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DETERMINATION OF THERMAL DOSE MODEL PARAMETERS
USING MAGNETIC RESONANCE IMAGING

Christopher James MacLellan, B.S.
Advisory Professor: R. Jason Stafford Ph.D.

Magnetic Resonance Temperature Imaging (MRTI) is a powerful technique for noninvasively
monitoring temperature during minimally invasive thermal therapy procedures. When coupled with
thermal dose models, MRTI feedback provides the clinician with a real-time estimate of tissue
damage by functioning as a surrogate for post-treatment verification imaging. This aids in
maximizing the safety and efficacy of treatment by facilitating adaptive control of the damaged
volume during therapy. The underlying thermal dose parameters are derived from laboratory
experiments that do not necessarily reflect the surrogate imaging endpoints used for treatment
verification. Thus, there is interest and opportunity in deriving model parameters from clinical
procedures that are tailored to radiologic endpoints.
The objective of this work is to develop and investigate the feasibility of a methodology for
extracting thermal dose model parameters from MR data acquired during ablation procedures. To
this end, two approaches are investigated. One is to optimize model parameters using posttreatment imaging outcomes. Another is to use a multi-parametric pulse sequence designed for
simultaneous monitoring of temperature and damage dependent MR parameters. These
methodologies were developed and investigated in phantom and feasibility established using
retrospective analysis of in vivo thermal therapy treatments. This technique represents an
opportunity to exploit experimental data to obtain thermal dose parameters that are highly specific
for clinically relevant endpoints.
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Introduction
Minimally invasive, image-guided thermal ablation therapies are increasingly being
incorporated into clinical practice as an alternative to traditional surgery. This trend is largely driven
by synergy with advanced imaging modalities during treatment planning, monitoring, and
assessment. In particular, real-time temperature monitoring using Magnetic Resonance
Temperature Imaging (MRTI) can be a powerful tool for guiding these procedures when coupled to
appropriate thermal dose models. MRTI acts as a surrogate to post-treatment imaging that provides
a means for assessing procedure progress, safety, and efficacy in real-time. This is useful in that
post-treatment verification imaging often takes time, or makes use of injected contrast agents, to
assess the procedure efficacy.
On a fundamental level, thermal dose models predict the probability of observing an effect
of interest (EOI) after a given thermal exposure. Clinically utilized thermal dose models typically
assume that the onset of an EOI can be modeled as an Arrhenius process and rely almost exclusively
on empirical parameters derived from laboratory experiments. This is direct consequence of the
underlying Arrhenius kinetics, which generally demand that temperature be precisely monitored
and controlled throughout the experiments. However, the gold standard for treatment assessment
is based on radiologic EOIs that exploit irreversible changes in MR parameters. Traditionally, this
encompasses post-treatment imaging of the thermal lesion using one or more contrast mechanisms,
although intra-treatment changes in intrinsic MR parameters have also been associated with
irreversible changes in tissue. This incongruity between the dose monitoring and assessment makes
a method for extracting thermal dose model parameters directly from radiologic data of interest.
Such a technique would provide predictions that are more closely aligned with clinical endpoints
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and provide an opportunity to leverage ever increasing amounts of patient data for continual
refinement.
Therefore, the hypothesis of this research is that the MR imaging information acquired
during thermal ablation procedures can be used to derive unique Arrhenius based thermal dose
model parameters for MR observable effects of interest in vivo. This hypothesis will be tested by
completing the following specific aims:
Specific Aim 1: Design and validate a multi-parametric pulse sequence suitable for
monitoring multiple temperature dependent MR parameters with high temporal and spatial
resolution.
Arrhenius damage models are parameterized by two empirically derived constants and
predict the onset of an EOI as a function of tissue temperature-time history. Deriving these
constants requires monitoring tissue temperature and measuring the specified EOI. While it is
possible to construct a MR-derived model of thermal dose solely using post-treatment imaging,
several damage dependent intrinsic MR parameters that have been associated with irreversible
damage may be able to provide complementary information when monitored simultaneously with
temperature. The working hypothesis in this aim is that the abrupt changes in the linearity of the
temperature dependence of relaxation rates T1 and T2* associated with irreversible tissue changes
can be accurately measured during heating. In order to investigate this hypothesis, a multi-echo
gradient-recalled echo pulse sequence will be modified so that flip angles can be alternated
throughout the acquisition to facilitate simultaneous measurements of T1, T2*, and PRF during
heating.
Specific Aim 2: Develop and characterize an experimental and computational
methodology for estimating thermal dose model parameters for MR-observable EOIs and validate
in phantom.
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Traditionally, experiments for developing Arrhenius models of thermal dose have been
restricted to the laboratory due to the transcendental nature of the governing equations and
measurements. The working hypothesis in this aim is that the MR temperature information
collected during thermal therapy delivery can be coupled with independent MR imaging information
acquired during or after therapy to obtain Arrhenius model parameters that are predictive of the
imaging EOIs. Using multi-parametric feedback (SA1), post-treatment imaging, and nonlinear
regression algorithms, a technique will be developed for training Arrhenius models for intra- and
post-treatment radiologic EOIs. This method will be validated to heating experiments in a protein
coagulation phantom that can be well controlled and compared to literature values.
Specific Aim 3: Derive and validate MR based damage models from in vivo human data
using the methodology outlined in SA2.
To demonstrate feasibility of deriving thermal dose model parameters from MR data, the
methods developed in SA2 will be investigated in in vivo ablation procedures. The optimal dose
model parameters will be investigated by retrospectively analyzing laser ablation (N=5) procedures
in human brain and using contrast enhanced T1-weighted imaging as an EOI. These parameters will
be critically compared to existing literature both in terms of values and predicted areas of damage.
The organization of the dissertation is thus. Chapter 2 begins with a broad overview of
thermal therapies followed by an examination of the role of MR during treatment planning,
monitoring and assessment. Chapter 3 takes an in depth look at the theoretical basis of thermal
dose models and previous investigations into different models. Chapters 4, 5 and 6 address specific
aims 1, 2, and 3, respectively.
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MR Guided Thermal Therapy
2.1 Introduction
Thermal therapies are clinical procedures where an external energy source is used to
elevate the temperature of target tissue to achieve a therapeutic effect. The development of noninvasive imaging techniques has played a large role in the adoption of thermal therapies into the
clinic and is critical in each of four stages common to all thermal therapy procedures: planning,
targeting, monitoring, and asessment.1 MR is particularly well suited to these tasks due to its ability
to image in arbitrary planes, lack of ionizing radiation, and the ability to exploit a variety of contrast
mechanisms that are uniquely suited for each stage of the procedure.

2.2 Thermal Therapies
Thermal therapies that employ heating can be broadly categorized into two general
regimes: thermal ablation and hyperthermia. In the former tissue temperature is raised to relatively
high temperatures for short periods to destroy tissue via acute thermal injury whereas hyperthermia
uses relatively low temperatures to sensitize tissue to other treatments.
2.2.1 Thermal Ablation
Ablation procedures are characterized by high temperatures (>50 ⁰C) maintained for short
durations (seconds-minutes) where the primary goal is an immediate catastrophic and irreversible
breakdown of structural proteins called coagulative necrosis.2 These procedures have several
advantages over conventional surgery and are predominantly used in the ablation of cancerous
tumors. Procedures are designed to be noninvasive or minimally invasive, which better preserves
surrounding tissues, and are associated with lower morbidity and complications. Consequently,
much of the attractiveness of the procedures are because they are associated with shorter
hospitalization times and reduced cost relative to open surgery. They also represent the only
4

treatment option in situations where surgery is contraindicated and are repeatable in case of
recurrence.3
A variety of modalities exist for delivering thermal energy including radiofrequency ablation
(RFA), microwave ablation (MWA), laser ablation, and high intensity focused ultrasound (HIFU).4 The
two most commonly used techniques, RFA and MWA, utilize percutaneously administered
electrodes and antennas, respectively, to heat surrounding tissue using electromagnetic energy.
Both methods have been used in a variety of malignancies and are commonly used in the liver,
lungs, bone and kidneys.3,5,6 MWA is associated with faster heating and larger ablation zone and is
used for larger tumors (5-8cm) whereas RFA is used for smaller tumors (<3cm).3,5 Despite the
theoretical advantages provided by MWA, RFA remains in widespread clinical use because it is a
more mature and established technology with greater familiarity among physicians. Generally,
image guidance is provided by computed tomography or ultrasound for probe placement and the
ablation zone is identified using post treatment imaging, usually via administration of exogenous
contrast agent to assess the region of perfusion deficit.7 Temperature is typically not monitored
during these procedures using computed tomography or MRI due to dose considerations and
electromagnetic interference, respectively.
Laser ablation is a third method for thermal ablation that uses a percutaneously
administered laser fiber to ablate surrounding tissue. These procedures are less common than both
RFA and MWA, mostly due to a reduced effective ablation zone (1-2cm).2 One inherent advantage is
that the laser does not interfere with MRI signal acquisition allowing temperature to be monitored
in real-time using magnetic resonance temperature imaging (MRTI) techniques. The ability to
monitor in real-time coupled with the relatively small ablation zone make laser ablation a precision
technique that can maximize normal tissue sparing and be used in close proximity to critical
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structures. For this reason laser ablation has been utilized in additional anatomic sites such as the
brain, spine, prostate, and head and neck.8–12
A fourth clinically used method for thermal ablation is high-intensity focused ultrasound
(HIFU). HIFU is a noninvasive procedure where an array of ultrasound transducers is focused onto a
point of interest to raise the tissue to ablative temperatures. Each individual sonication achieves
coagulative necrosis in a matter of seconds over a limited area (≈0.5cm) and many of these
sonications are performed to cover an entire target area. HIFU is unique in that it typically relies on
MRTI to confirm proper delivery of thermal energy. HIFU is one of the oldest methods of thermal
ablation and has been investigated in a variety of sites13 including breast, prostate, uterus14, liver,
and bone15. Traditionally, this procedure has been limited by high attenuation in bone but recent
technological advances have led to specialized devices for transcranial ablation. 16–18
In each of these procedures the primary method for evaluating the extent of thermal
damage is diagnostic imaging. This often includes injection of exogenous contrast agents to evaluate
perfusion in tissue. MR is particularly well suited for these types of evaluations as many contrastmechanisms are available to evaluate different physiological effects. (section 2.6.3)
2.2.2 Hyperthermia
The second temperature regime for thermal therapies is hyperthermia which is
characterized by moderate loco regional temperature (39-45⁰C) increases in tissue temperature
over long time scales (101-102 minutes). Unlike ablation, the primary goal of hyperthermia is to
sensitize malignant tissue to another treatment modality such as radiation therapy, chemotherapy,
or immunotherapy.19 As such, hyperthermia is typically considered for oncologic applications. While
hyperthermia has been the subject of research since the 1970s, it has experienced resurgence over
the last decade due to advances in delivery and monitoring mechanisms and greater understanding
of the underlying physiologic processes. Various techniques have been used to bring all or part of
6

the body to hyperthermic temperatures including conduction, electromagnetic energy and focused
ultrasound.

2.3 MR for Thermal Therapy Planning
Thermal therapy planning encompasses the identification of the therapeutic target and the
guidance of the external energy source to that target. Several contrast mechanisms can be exploited
to identify a target and the surrounding critical structures by adjusting MR sequence parameters.
Basic T1-weighted and T2-weighted pulse sequences often provide sufficient contrast but
exogenous T1 contrast agents may be administered to delineate tumor margins in some oncologic
cases.

2.4 MR for Thermal Therapy Targeting
Once the target is identified, additional imaging is used to direct the external energy source
to the target. Real-time anatomic imaging is used to guide the probe to the target for percutaneous
ablation techniques. Computed tomography and ultrasound (US) are the most commonly used for
this purpose, particularly in body procedures. MR plays a larger role in cases with small and/or
difficult to identify tumors or in in sensitive areas such as the prostate, brain, head, and neck that
require MRTI monitoring.9,20 FUS procedures are unique in that they require MR or US to confirm
good acoustic coupling between the patient and the ultrasound transducers before treatment. 2122

2.5 MR for Thermal Therapy Monitoring
MR is unique in that it is capable of noninvasively monitoring temperature during thermal
therapy procedures. This can be a critical component to ensuring the safety and efficacy of the
procedure, particularly when performed in close proximity to critical structures. CT is also
theoretically capable of monitoring temperature but requires repeated acquisitions at an increased
radiation dose.23,24 However, due to the repeated RF pulses needed to acquire MR images, MRTI
7

techniques are restricted to laser and HIFU procedures unless special triggering equipment, filtering,
and/or processing are used.25 Just as in anatomic imaging, there are multiple contrast mechanisms
that can be used to acquire MRTI data.
2.5.1 Proton Resonance Frequency
The most commonly used contrast mechanism for MRTI procedures is the proton resonance
frequency (PRF). The complex MRI signal for a spoiled gradient echo acquisition at a fixed flip angle
is given by:
1

𝑇𝐸

𝑆 = 𝑆0 𝑒 −𝑇𝐸(𝑇2∗−2𝜋𝑖∆𝑓) = 𝑆0 𝑒 −𝑇2∗ 𝑒 𝑖𝜑

2-1

Where S is the complex valued signal, TE is the echo time, 𝑆0 is the signal magnitude at TE=0
ms, T2* is the transverse relaxation time, ∆𝑓 is the resonance frequency in the rotating frame of
reference, and 𝜑 is the signal phase. The dependence of the proton resonance frequency of water
protons with temperature has been shown to be linear and is given by:
∆𝑇 = 𝛽∆𝑓

2-2

Where 𝛽 is the temperature sensitivity coefficient with a value of approximately -0.01
ppm/⁰C.26,27 The primary advantages of using the PRF shift for MRTI are that the temperature
dependence is linear and largely tissue independent (with the notable exception of adipose tissue).
The most common challenges result from sensitivity to other effects that can alter the resonance
frequency. 𝐵0 shifts caused by motion present a significant challenge and several techniques have
been developed to address this in clinical scenarios.28–30 Field drift caused by heating in gradient
coils over long acquisition times contributes a bias to temperature measurements and can be
corrected by subtracting the temperature increase in reference region provided the phase drift is
sufficiently uniform across the image. Like many other MRTI techniques, the PRF technique can only
give relative changes in temperature so a baseline must be measured or assumed.
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There are two primary approaches for measuring temperature using changes in the PRF. The
first and most common is the complex phase difference (CPD) method where a single gradient echo
is acquired at each time point and the temperature is calculated from the difference between
successive phase images via:

∆𝑇 =

tan−1 (𝑆 ∗ 𝑆 ∗ )
𝛽𝛾𝐵0 𝑇𝐸

2-3

where the phase difference is explicitly calculated in complex space to avoid phase wrapping
errors.
The CPD method can be implemented on fast gradient echo or echo planar imaging
sequences to maximize coverage in the slice direction and/or temporal resolution. SNR can be
optimized by choosing TE=T2*, which balances the increased in phase difference with the
simultaneous loss of signal magnitude as TE is increased. The primary drawbacks are that it relies on
a single measurement to calculate the resonance frequency and there is an implicit assumption that
the water is the only chemical species in each voxel. Additional chemical species in the voxel(s) will
corrupt the measurements if the signal is not suppressed. For this reason, traditional fat/water
separation techniques such IR-preparation, fat saturation, and Dixon, may be needed to obtain
reliable results from PRF.31
Another approach to using the PRF shift to measure temperature is to perform chemical
shift imaging techniques to directly measure the PRF.32–34 Practically, this requires measuring
multiple echo times at each time point at the cost of spatial and/or temporal resolution. If it can be
safely assumed that water is the only chemical species present in the voxel the resonance frequency
can be found by linear regression that is theoretically more precise than the single point
measurement in the CPD method and also more likely to encompass the optimal echo time.
Alternatively, spectral methods can be used to separate chemical species on a voxel basis and the
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water resonance frequency can be extracted for purposes of temperature calculation. Using this
technique, signal from multiple chemical species can be detected and the non-temperature sensitive
lipid signal can theoretically be used as an internal frequency reference and/or to calculate absolute
temperature. 35
2.5.2 Longitudinal Relaxation Time (T1)
A second MR parameter that has been shown to be temperature dependent is the
longitudinal relaxation time, T1. During T1 relaxation spins in an excited state return to thermal
equilibrium after exchanging energy with the surrounding molecular lattice. In physiological
samples, this phenomena is primarily caused by intermolecular rotational motion of water
molecules creating a time varying magnetic field at the resonance frequency, 𝜔,. This contribution
to relaxation can be written:
1
2𝜏𝑐
8𝜏𝑐
= 𝑘[
+
]
2
2
𝑇1
1 + 𝜔 𝜏𝑐 1 + 4𝜔 2 𝜏𝑐2

2-4

Where 𝜏𝑐 is the correlation time (the average time it takes for the molecule to rotate one
radian), and 𝐶 is a constant. The rotational speed of the water molecules is governed by the
Boltzmann distribution so the temperature dependence of the 𝜏𝑐 can be written:
𝜏𝑐 = 𝜏0 𝑒 𝐸𝑐 /𝑘𝑇

2-5

Where 𝑘 is the Boltzmann constant, 𝑇 is the temperature (°K), 𝜏0 is the correlation time at
𝑇 = ∞, and 𝐸𝑐 is the activation energy of the rotation process. Correlation times are on the order of
10-12s in pure water which allows the frequency dependent dispersion terms to be neglected
(𝑖. 𝑒. 𝜔2 𝜏𝑐2 ≪ 1) and the following approximation for the temperature dependence of T1:
𝑇1 ∝ 𝑒 −𝐸𝑒𝑓𝑓 /𝑘𝑇

2-6

Which implies that T1 has an approximately inverse relationship with temperature if the 1st order
terms of the Taylor series expansion are used. 36,37
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𝑇1 ∝ 1/𝑇

2-7

The above derivation explicitly assumes that the signal comes from pure water with
extremely short correlation times. In tissue, the presence of large macromolecules causes the
surrounding water molecules to form a hydration layer where motion is restricted and correlation
times are decreased. It is generally accepted that these different hydrogens populations undergo
fast exchange with one another and that the observed T1 is a weighted average of these different
populations. 36
𝑁

1
1
(𝜏 )
= ∑ 𝑓𝑖
𝑇1
𝑇1𝑖 𝑖

2-8

𝑖=1

Where 𝑓𝑖 is the fraction of hydrogens contained within each population, or more generally
for a continuous distribution of correlation times 𝑔(𝜏𝑐 ):37
∞
1
1
= ∫ 𝑔(𝜏) (𝜏)𝑑𝜏 ′
𝑇1
𝑇1
0
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Fung and colleagues38–40 showed that the temperature dependence of the hydration layers
water can be accurately modeled by assuming that the correlation times follow a log-normal
distribution and numerically solving equation 2-4. Their results suggests that temperature
dependence of these hydration layer waters is negligible and equation 2-7 remains a reasonable
appproximation.41
While an inverse relationship between T1 and 𝑇 is expected from equation 2-7 it has been
shown to be effectively linear over the relatively small range in absolute temperatures required for
physiological samples. 42 This linear relationship is attractive for temperature monitoring and has
been measured in the range of 1-2% in tissue. However, there are several drawbacks to measuring
T1 for temperature monitoring. The temperature dependence is tissue dependent and has to be
calibrated in each type of tissue being used. The temperature sensitivity also changes abruptly in
response to physiologic changes in tissue caused by heating which makes using T1 as a primary
11

measure of temperature problematic.43–45 Additionally, the time required to make T1 measurements
is limiting in the context of temperature monitoring. Traditional inversion recovery (IR) methods
require several minutes to acquire multiple inversion times. Accelerated methods for sampling the
magnetization recovery exist but typically requires minutes to acquire an image compared with
seconds for PRF techniques46–48 An alternative approach is the estimate T1 using variable flip angle
(VFA) technique. This technique is especially sensitive to slice profile effects inherent to 2D imaging
so it is generally necessitates a 3D acquisition with acquisition times on the order of minutes. 49 For
these reasons temperature monitoring using T1 has been used as a complement to PRF monitoring
in a research settings or in hyperthermia applications where temporal resolution is less critical.32,50,51
2.5.3 Transverse Relaxation Times (T2/T2*)
The transverse relaxation time (𝑇2 ) can also be written in terms of the intermolecular
rotation of water molecules36,52:
1
5𝜏𝑐
2𝜏𝑐
= 𝑘 [3𝜏𝑐 +
+
]
2
2
𝑇2
1 + 𝜔 𝜏𝑐 1 + 4𝜔 2 𝜏𝑐2
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Where the non-frequency dependent term represents static alterations in the magnetic field
that cause rapid loss of phase coherence. Unlike T1 relaxation, which requires field alterations that
match the resonance frequency, the T2 relaxation time is sensitive to lower frequency field
variations. While the expression in equation 2-10 is adequate for predicting T2 in non-viscous liquids
such as pure water, it fails to explain why T2 values are 5-10 times lower than T1 in tissue. This
observation coupled with the lack of observed frequency dependence of T2 values suggests that
other mechanisms contribute significantly T2 relaxation.36,37,53 This is typically attributed to diffusion
of water molecules through static field inhomogeneities in the hydration layer.54,55 The contribution
of these processes are highly dependent on the specimen being imaged and makes a theoretical
relationship between T2 and temperature elusive.
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Early experiments by Belton56,57 showed non-monotic temperature dependence at
temperatures below room temperature but T2 has been empirically found to increase nonlinearly
with temperature in the physiological range.58 The relative increase is generally smaller compared to
the simultaneous increase in T141 and shows similar nonlinear behavior when the structure of tissue
is altered by coagulation59,60. Aside from the nonlinear nature and reduced sensitivity to
temperature, measurement of T2 for temperature monitoring is impractical due to the long
acquisition times required to acquire T2 maps compared to T1 maps.
When a gradient echo acquisition technique is used a relaxation rate, T2* is measured:
1
1
1
+ ′
∗ =
𝑇2 𝑇2 𝑇2
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Where 𝑇2′ represents the dephasing caused by macroscopic magnetic field inhomgeneities from
macroscopic susceptibility interfaces and the imperfect B0 field that are traditionally refocused in
spin echo type sequences. Few researchers have examined the temperature dependence of T2* but
it is expected to follow the same dependence at T2 with a near constant contribution form field
inhomogeneities. One notable exception may be found as susceptibility interfaces where the small
but nonzero temperature dependence of magnetic susceptibility may contribute a temperature
dependence of 𝑇2′ (see section Magnetic Susceptibility). One study by Taylor et al. qualitatively
confirmed this behavior by observing increases in T2* with increasing temperature until samples
reached temperature typically associated with coagulation. While T2* inherently suffers from most
of the same limitations as T2 for temperature monitoring, it can be mapped with much faster multiecho gradient echo sequences and is a potential complement to traditional PRF monitoring given its
sensitivity to changes in tissue state.
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2.5.4 Magnetization Transfer (MT)
Magnetization transfer (MT) is MR contrast mechanism that is sensitive to protons in the
hydration layers of macromolecules and is closely related to the theory of T1/T2 relaxation
described in sections 2.5.2 and 2.5.3 . Protons in the hydration layer see a range of local magnetic
fields which results in inefficient excitation by on resonance pulses and extremely short T2s. In a MT
experiment an off resonance pulse is applied after which the saturated protons undergo fast
exchange with free water. When a traditional imaging sequence follows the MT pulse the observed
signal decreases due the exchange of these saturated hydration layer protons with the free water
pool. The traditional quantity of interest in these experiments is the magnetization transfer ratio
(MTR)
𝑀𝑇𝑅 = 1 −

𝑀𝑀𝑇
𝑀0

2-12

Wher 𝑀𝑀𝑇 is the signal after the magnetization transfer pulse and 𝑀0 is the signal without
the magnetization transfer pulse.61
The exchange mechanisms characteristic of MT are temperature dependent and have been
investigated as a method for monitoring temperature. However, there are conflicting reports of
whether MTR increases or decreases with temperature59,62,63 The response appears to be highly
tissue dependent and possibly sensitive to competing interactions involving macromolecules in the
sample. Similar to T1 and T2, nonlinear changes in MT temperature dependence are associated with
changes tissue state which limit its use for temperature monitoring but make it of interest for
monitoring tissue damage. MT pulses can be implemented relatively easily into traditional gradient
echo temperature monitoring techniques as a complement to traditional PRF monitoring. However,
this comes with a loss of SNR and slightly increased acquisition time. Additionally, the choice of echo
time(s) must be chosen judiciously to balance the competing need of high SNR for MT contrast and
the temperature sensitivity of the PRF.62
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2.5.5 Diffusion
Diffusion of water protons is another temperature dependent MR parameter that can be
measured when diffusion sensitizing gradient are employed. If all other sequence parameters are
held constant the addition of these gradients is given by
𝑆 ∝ 𝑆0 𝑒 −𝑏𝐷
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Where 𝑏 is a characteristic parameter of the diffusion sensitizing gradients and 𝐷 is the
diffusion coefficient. The temperature dependence of the diffusion coefficient, 𝐷, is similar to T1 as
it is also governed by the Boltzmann distribution:
𝐷 ∝ 𝑒 −𝐸𝐷 /𝑘𝑇

2-14

Where 𝐸𝐷 is the activation energy of the diffusion process. Diffusion has a relatively high
temperature sensitivity of approximately 2% per degree and has been employed for temperature
monitoring phantoms64–66 and in vivo67,68. However, long imaging times and sensitivity to motion
make practical implementation in vivo difficult. 26,69 Like T1 and T2, diffusion values also respond
nonlinearly to changes in tissue state and is of interest for directly monitoring damage to tissue.26
2.5.6 Magnetic Susceptibility
The available longitudinal magnetization, 𝑀0 , for a given MR experiment is directly
proportional to magnetic susceptibility, 𝜒0 , of the material being imaged which has a temperature
dependence governed by the Curie law:
𝑆0 ∝ 𝜒0 ∝

1
𝑇
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The magnetic susceptibility cannot be easily isolated in an MR experiment so this
temperature dependence practically manifest as a decrease in signal. The dependence is relatively
small and on the order of 0.3%/°C.26 This small temperature dependence combined with the long
imaging times required to remove relaxation effects from the observed signal make it a poor choice
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for direct temperature monitoring. However, it is important to consider this dependence in certain
situations such as at susceptibility interfaces70 and when interpreting changes in signal intensity with
temperature rather than maps of other intrinsic MR parameters.
2.5.7 Thermal Dose
MRTI is an integral part of monitoring thermal therapies but knowledge of the temperature
history alone does not elucidate the state of treated tissue. Thermal dose models are needed to fully
understand the effect of heat on tissue. In the most general sense a thermal dose model is a
mathematical relationship that converts a temperature history into a probability of having some
effect on tissue. These models can vary widely in complexity and their applicability is highly
dependent on the procedure in question. On one extreme, tissue that reaches temperatures of 100
degrees Celsius is certainly nonviable, and a simple threshold model based on the maximum
temperature is sufficient. For hyperthermia applications where temperatures are relatively low and
treatment times are long, the relationship between temperature history and biological effect cannot
be understood through intuition alone. Given the diffusive nature of heat, temperature histories
between these extremes are unavoidable, with the possible exception of the highest power short
duration FUS and LA procedures. A detailed treatment of thermal dose models and clinically
relevant biological effects is left to Chapter 3.
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2.6 MR for Thermal Therapy Assessment
The gold standard method for assessing the biological effects of ablation procedures is
examination of the thermal lesion using histology. However, histologic examination is impossible to
incorporate into the routine clinical workflow. Consequently, post-treatment imaging is the primary
surrogate for assessing damage after therapy and providing a baseline for follow-up imaging and are
integral to monitoring disease progression. While T2-weighted (T2-W) imaging and contrast
enhanced T1-weighted (CE-T1-W) are routinely used in the clinic to identify the extent of the
thermal lesion there are many additional MR contrast mechanisms that have been investigated to
investigate various biological responses to thermal injury in tissue.
2.6.1 Physiology of the Thermal Lesion
The thermal lesion that occurs after an ablation procedure consists of two zones
characterized by the physiological state of tissue.2,4 The central zone is the area immediately
surrounding the probe or FUS focus that receives the highest thermal dose. This area is
characterized by a catastrophic breakdown in cellular and tissue function. Immediately outside the
central zone is the peripheral or transition zone that consists of a mixture of tissue that will become
nonviable via delayed processes such as apoptosis and tissue that will recover from reversible
thermal injury. This zone is of primary interest as it borders untreated tissue and contains the
margin of clinically meaningful damage. The biological processes governing the fate of tissue in this
region are numerous and interconnected. They include but are not limited to: mitochondrial
damage, DNA damage, induction of apoptosis and inflammatory immune response. Blood vessels
are also disrupted in this zone, causing accumulation of fluid and local swelling.71,72 In hyperthermia
treatments, the central zone is absent since the objective is to modulate the biologic processes in
tissue. The entire treated region can be considered analogous to the peripheral zone in ablation,
albeit with exclusively sub lethal biological effects.
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2.6.2 Clinical Imaging of the Thermal Lesions
When MRI is employed for guidance of a clinical ablation procedure, the most commonly
used MR techniques for visualizing thermal lesions are T2-weighted (T2-W) imaging and contrastenhanced T1-weighted (CE-T1-W) imaging.1,73 Lesions are characterized by a nonenhancing central
region that can be either hypo- or hyperintense with respect to surrounding normal tissue
depending on tissue type and the time elapsed since treatment. For high temperature ablations,
vascular stasis and the region of irreversible tissue damage are closely linked. Therefore, lack of
enhancement on contrast-enhanced imaging is the most consistent attribute of this region so
contrast is indicated and is often visualized using subtraction imaging. This region is generally
considered to be synonymous with the central zone described in section 2.6.1 and contains only
nonviable tissue. A peripheral region of altered intensity and/or contrast enhancement often
develops following ablation and is attributed to leakage of contrast agent into the interstitial space
due to damage to the vasculature and accumulation of fluid and/or inflammation-induced
hyperemia.73–78 This region is consistently observed in the brain where it expands in the first 1-40
days after treatment before reducing to pretreatment size within 16 weeks where it will continue to
enhance on long term follow up.74,79,80
While a lack of enhancement is MR imaging can identify the central zone, the viability of
tissue in the peripheral enhancing region is more nuanced. Some studies in the brain that have
attempted to correlate this region with histology suggest that the enhancing/hyperintense ring
remains viable81–83 whereas others have suggested the opposite7,84–87. Given the complexity of the
biological response, considerable uncertainties associated with registering images to histology, and
the fact that the size of the hyperintense/enhancing rim changes over time makes a definitive
determination on the viability of tissue in this region a challenge.88
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2.6.3 Multi-Parametric Imaging of the Thermal Lesion
Several advanced MR techniques have been investigated for imaging thermal lesion that are
potentially sensitive to specific biological effects in the peripheral zone. These have not been
incorporated into routine clinical practice primarily due to time constraints and lack of consensus
regarding their clinical utility. T1, T2, MT and diffusion were discussed in section 2.5 in the context of
their temperature dependence and each suffered from the limitation that their dependence became
nonlinear at high temperatures. At these high temperatures there is a complex interaction of
different physiological effects that cause changes in intrinsic MR parameters. These include
disruption of cellular membranes that restrict diffusion, denaturation and coagulation of proteins
and blood, and increased fluid in the peripheral zone. These processes can have opposite effects on
intrinsic MR parameters that manifest as changes that are highly dependent on tissue type. Variable
results have been observed in a variety of ex vivo59,63,89,90 and in vivo91–93studies. Generally, a
consistent decrease in T1 is observed across a variety of tissue types while changes in T2 and MT are
varied. Inconsistent changes in the apparent diffusion coefficient (ADC) have also been observed.
Jacobs 94 et al observed an initial decrease in ADC immediately following FUS ablation of uterine
fibroids but observed an increase upon 6 month follow up. This underscores that thermal effects in
tissue are not static and can be highly dependent on when follow up imaging is performed. Dynamic
contrast enhanced (DCE) MRI has also been investigated to evaluate the viability of the thermal
lesion. In this technique, the uptake of intravenously injected contrast agent is monitored using
serially acquired T1-weighted images to assess perfusion in tissue. Studies in animals92,95,96 and
humans96 have associated changes in semi-quantitative and quantitative DCE parameters with
regions that were distinct from the non-enhancing volume on traditional CE-T1-W imaging.
While multi-parametric imaging of thermal lesions is still investigational and has not been
standardized for clinical use, these techniques have the potential to elucidate the complexities of
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the biologic response in the thermal lesion. In a series of recent papers91,92, Hectors et al. correlated
the post-treatment measurements of several of MR parameters with histology. They found that no
single MR parameter was sufficient for predicting damage in tissue and that a more specific
prediction of the nonviable region could be made by applying clustering techniques to multiple
parameters. These results suggest that multi-parametric techniques may provide complementary
information to current clinically utilized methods and further investigation in clinical models is
warranted. These results not only suggest that multiple MR contrast mechanism should be used for
evaluating the thermal lesion but also that multiple thermal dose models that reflect each of these
contrast mechanism may be most appropriate for monitoring.
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Thermal Dose Models
3.1 Introduction
Like any intervention, thermal therapies are only of clinical utility if the balance between
therapeutic efficacy and patient safety is understood. In section 2.5 MRTI was described as a tool for
monitoring these procedures in real-time. However, to maximize the utility of MRTI the measured
temperature histories must be converted by some model into values predictive of thermal damage.
Intuitively, one knows that the primary variables are the temperature and the duration of exposure
and that there is some degree of variation in different tissues. Therefore, in principle, a thermal
dose model should be able to predict the onset of a thermal damage for an arbitrary temperature
history for a particular tissue. Several different models of thermal dose have been developed that
vary widely in complexity and applicability to different types of thermal therapies. However, three
models dominate the literature: The absolute rate (AR), the cumulative effective minutes (CEM), and
critical temperature (CT) model.

3.2 Effects of Interest (EOIs) and Isoeffects
The defining characteristic of a thermal dose model is the effect of interest (EOI) that it is
designed to predict. Many different EOIs have been used for thermal dose models and are
intimately related to the experimental techniques used to measure them. EOIs can be categorized as
quantitative or categorical based the types of data (in a statistical sense) that define them. They can
also be categorized as intra-treatment effects or post-treatment effects based on when they are
measured. For example, cell survival is a quantitative and post-treatment EOI since it is represented
by a quantitative quantity (e.g. 63% cell survival) that can only be measured after thermal exposure.
It is often useful to discuss these effects in terms of a specific value of the EOI, or isoeffect. In the
previous example cell survival is the EOI and 63% survival is an isoeffect. In the special case of
21

categorical EOIs this distinction becomes trivial if the data are binary (e.g. enhancing/non-enhancing
on post-treatment imaging). The subtle distinction between the types of EOIs and isoeffects are
concepts are critical when discussing the theoretical basis of each thermal dose model.

3.3 Absolute Rate (AR) Model
3.3.1 Theory
The Absolute Rate (AR) model of thermal dose approximates a given EOI as a first-order
irreversible reaction. Such a reaction can be described conceptually as

𝑁→𝐷
𝑘

3-1

Where a sample the in a native state, N, is irreversibly converted into a denatured state, D,
with conversion rate k. If this process is assumed to be first order it can be described using a
differential equation:

𝑑𝑁
= −𝑘𝑁
𝑑𝑡

3-2

𝜏
𝑁0
𝑙𝑛 ( ) = ∫ 𝑘𝑑𝑡
𝑁
0

3-3

With solution:

The conversion rate can be related back to fundamental thermodynamic quantities using
the Eyring equation from transition state theory

𝑘=

𝑘𝐵 𝑇 −Δ𝐺∗
𝑒 𝑅𝑇
ℎ
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Where 𝑘𝐵 is the Boltzmann constant, T is the temperature (⁰K), ℎ is Planck’s constant, R is
the universal gas constant, and Δ𝐺 ∗ is the Gibbs’ free energy of formation. Δ𝐺 ∗ can also be
expressed using the thermodynamic relation:

∆𝐺 ∗ = ∆𝐻 ∗ − 𝑇∆𝑆 ∗
22
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Where Δ𝐻 ∗ is the enthalpy of formation and ∆𝑆 ∗is the entropy of formation. The activation
energy for a first order reaction is given by:

𝐸𝑎 = 𝑅𝑇 + Δ𝐻 ∗ ≅ Δ𝐻 ∗
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Which a reasonable approximation for physiological processes which have 𝐸𝑎 ~105 and
𝑅𝑇~103. Combining equations 3-3 through 3-6 an Arrhenius relationship is obtained97,98:
𝜏
𝜏 −𝐸𝑎
𝑁0
Ω = 𝑙𝑛 ( ) = 𝐴 ∫ 𝑘𝑑𝑡 = 𝐴 ∫ 𝑒 𝑅𝑇(𝑡) 𝑑𝑡
𝑁
0
0
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Where Ω is a unitless damage parameter and the pre-exponential term defined as:

𝐴≡

𝑘𝐵 𝑇 Δ𝑆 ∗
𝑒 𝑅
ℎ
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Despite the explicit temperature dependence in equation 3-8, it is assumed to be
insignificant compared to the temperature dependence in the exponential term and is often treated
as a constant over the range of temperatures involved in thermal therapies.99,100 This constant,
dubbed the frequency factor, and the activation energy together make up what are called the
Arrhenius parameters and define the damage process for a given EOI. While Ω has been used
historically, its physical significance is not intuitive and its value increases exponentially to
impractically large values. Often a more practical quantity of interest is the fractional conversion
(𝐹𝐶):
𝑁(𝑡)
3-9
𝑁0
which is easily interpreted as the fraction of the sample that has been converted to the non𝐹𝐶(𝑡) = 1 − 𝑒 −Ω(𝑡) = 

native state and is bounded from 0 to 1.
3.3.2 Experimental Measurements
Measurement of the Arrhenius parameters is complicated by the transcendental nature of
equation 3-7 and cannot generally be solved analytically. Laboratory experiments are designed such
that 𝑇is constant101–105 (isothermal) or linearly increasing106–109 so that the right hand side of
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equation 3-7 can be solved analytically for 𝐴 and 𝐸𝑎 .This traditionally precludes the use of ablation
and hyperthermia data because of the inability to precisely control the temperature throughout the
experiment. The quantitative nature of Ω or 𝐹𝐶 make the AR model well suited for describing
quantitative EOIs provided they can be experimentally measured. In practice, quantitative
measurements in tissue are impractical or impossible for many relevant EOIs and many models are
derived from gross observations in the affected tissues that are categorical in nature. In these cases,
values of Ω or 𝐹𝐶 are typically arbitrarily assigned (e.g. Ω=1, 𝐹𝐶 = 63%) for a given EOI for the
purposes of model fitting.97,110 This is particularly challenging when using histopathological EOIs
which suffer from the additional uncertainties associated with relating the temperature history
location back to the area evaluated histopathologically.
A review of the kinetic parameters that define various biological processes can provide
additional insight into the effect of heat on tissue. Regardless of the type process being examined, a
plot of the activation energy versus of the log of the frequency factor approximately follows a
straight line. This empirical relationship has been measured independently by Rosenberg,111 and
Wright,112 and in this work we use the relationship measured by He and Bischof 98 (Figure 3-1):
log(𝐴) = 3.80 × 10−4 𝐸𝑎 − 9.36
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If this result is compare to theory by writing the frequency factor explicitly as a function of
the activation energy by combining equations 3-4 and 3-8 to obtain:
𝑙𝑛(𝐴) =

∆𝐸
𝑘𝑏 𝑇
∆𝐺 ∗
+ 𝑙𝑛 (
)−
𝑅𝑇
ℎ
𝑅𝑇

3-11

Comparing equation 3-10 and 3-11 shows that the slope is remarkably close to the range of
values of 1/RT in the ablation temperature range (3.9x10-4-3.3x10-4 for 90⁰C to 37⁰C). A constant
intercept implies only a small change (100-110 kJ/mol) in the Gibb’s free energy as a function of
temperature, which is characteristic of the thermal denaturation of proteins.98 This relationship is
incredibly useful as a rule of thumb when trying to ascertain the validity of measured coefficients.99
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In cases where non isothermal experiments are used to determine the Arrhenius coefficients this
relationship can be used as a constraint on the nonlinear optimization problem to make it more
tractable.108 A second trend that observed in the values is tendency for both the activation energy
and frequency factor to decrease in magnitude as temperature increases. This is seen in isothermal
experiments by the addition of a break point in the coefficients or in dynamic experiments as lower
activation energies for high end temperatures.
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Figure 3-1: Selected Arrhenius parameters. Arrhenius parameters compiled by Wright112 and He and Bischof98
for macromolecules (blue), tissues (red), and cells (green).The empirically derived He-Bischof line (black;
equation 3-10) shows the correlation between the experimentally measured values. The equivalent RCEM
values (magenta; equation 3-13) are shown as a function of activation energy for reference.

3.4 Cumulative Effective Minutes (CEM) Model
The CEM model is a fundamentally different approach to modelling thermal injury that
seeks to normalize the time required to reach an observed effect after a time history,𝑇(𝑡), to an
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equivalent exposure at a constant reference temperature, 𝑇0 . However, the CEM model still relies
on the same Arrhenius kinetics as the AR model. For isothermal exposures at two temperatures, 𝑇𝐴
and 𝑇𝐵 , the times, 𝑡𝐴 and 𝑡𝐵 , required to reach an arbitrary dose is defined by the reciprocal of the
rate, k, in equation 3-7. The ratio of these times is given by:
𝐸
− 𝑎

−𝐸𝑎
𝑡𝐴 𝑒 𝑅𝑇𝐵
𝑅𝑇𝐴 𝑇𝐵 )
 =
=
𝑒
(
𝐸
𝑡𝐵
− 𝑎

𝑒

(𝑇𝐴 −𝑇𝐵 )
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𝑅𝑇𝐴

In the special case of 𝑇𝐴 = 𝑇0 and 𝑇𝐵 = 𝑇0 + 1 a constant, 𝑅𝐶𝐸𝑀 , is defined by
−𝐸𝑎

𝑅𝐶𝐸𝑀 ≡ 𝑒𝑅(𝑇0 +1)𝑇0
If the exponential term in equation 3-14 is approximated by 𝑅𝐶𝐸𝑀 (i.e. temperature

3-13

dependence is negligible) and an arbitrary temperature distribution and single reference
temperature (i.e. 𝑇𝐴 = 𝑇0 and 𝑇𝐵 = 𝑇𝐵 (𝑡)) are considered the CEM model equation can be
derived:
𝜏

CEM = ∫ 𝑅𝐶𝐸𝑀 𝑇0 −𝑇(𝑡) 𝑑𝑡

3-14

0

Where CEM is the cumulative effective minutes and represents how long a similar
experiment would take if the temperature were held constant at the reference temperature.
The CEM model was originally developed for hyperthermia research at relatively low temperatures
(<47⁰C) which somewhat justifies the assumptions needed to derive equation 3-14 from 3-10 but
becomes suspect when extended to higher temperatures observed during ablation procedures.
These simplifications also demand that the value of 𝑅𝐶𝐸𝑀 be determined using an isothermal
experiments near the reference temperature. Early studies focused primarily on cell survival
measured in vitro for a variety of cells lines. However, as practical matter, the values chosen by
Sapareto and Dewey102 are used almost exclusively in thermal therapy literature. These values
correspond to 𝑅𝐶𝐸𝑀 of 0.5 and 0.25 for temperatures above and below 𝑇0 = 43°C, respectively. This
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model is referred to with the subscript “SD” (e.g. 𝑅𝐶𝐸𝑀−𝑆𝐷 ) to distinguish it from the more general
version in equation 3-13.
Despite being based on the same kinetics, the relative nature of the CEM model has
important practical implications. Unlike the AR model, which is inherently capable of predicting
quantitative EOIs, CEM values are meaningless without an associated isoeffect. Additionally, the
𝑅𝐶𝐸𝑀−𝑆𝐷 model implicitly assumes that the kinetics of all processes are the same which is not
supported by the 𝑅𝐶𝐸𝑀 dependence on activation energy from equation 3-13 (Figure 3-1).

3.5 Critical Temperature (CT) Model
The CT model differs from both the AR and CEM model in that the entire temperature
history is assumed to contribute negligibly to the prediction of thermal damage. Instead, tissue is
classified on whether it achieved some critical temperature, 𝑇𝑐 ,:
𝐷 = 𝐻(𝑚𝑎𝑥(𝑇(𝑡)) − 𝑇𝑐 )
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where 𝐻 is the Heaviside step function and 𝐷 = 1 and 𝐷 = 0 correspond to denatured and
native tissue, respectively. The maximum temperature term in equation 3-15 makes the CT model
especially sensitive to the noise and temporal resolution of temperature measurements. It also
limits its application to categorical EOIs. Since the time dependence of the onset of thermal damage
is ignored, this approach can only be realistically applied to single high temperature/short duration
exposures and explains its prominence in FUS literature.
Like the CEM model, the CT model can be connected back to the AR model. Taking the
derivative of equation 3-7 and setting it equal to an isoeffect of interest, Ω = Ω𝐶 , one can get a
second representation of the critical temperature (𝑇𝑐 ′):
𝑇𝑐 ′ =

𝐸𝐴


𝐴
𝑅 (ln Ω )
𝐶
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which represents the temperature that will result in the dose of interest if achieved
instantaneously. While these quantities are roughly analogous, 𝑇𝑐 ′ is theoretical in nature and
implicitly assumes that the temperature history is a delta function whereas measurements of 𝑇𝑐 are
practically convolved with previous temperature exposure. As such, one should expect 𝑇𝑐 ′ to be
higher than 𝑇𝑐 .

3.6 Application to Thermal Therapies
Each of the previously described dose models have been applied in thermal therapies.
Traditionally, the focus of previous research has been to measure Arrhenius or CEM parameters in
the laboratory and correlate the calculated doses with a categorical EOIs observed using imaging or
histology. Few studies87 have attempted to derive model parameters directly from histologic or
radiologic endpoints due to the inability to control the temperature with high precision.
The Henriques97 skin burn model (Ω = 1) has been correlated with acute coagulative
necrosis observed on H&E stained samples113 and has been incorporated into a commercial laser
ablation system. Sherar et al.114 examined the correlation of three different models with posttreatment imaging and histology after MWA in rabbit brain. The Jacques103 model correlated with
the central region on post-treatment T2-W imaging while the Borrelli104 and Brown105 models
correlated with the transition region using an isoeffect of Ω = 4.9. However, this agreement was
found to be insensitive to the chosen isoeffect, an observation that was corroborated by Yung115 in
canine brain. This is attributed to the exponential nature of equation 3-7 which causes rapid dose
increases. While the corresponding uncertainty in dose threshold may be inconsequential for
experiments with high dose gradients, it is expected to have a larger impact for procedures involving
lower temperatures and longer exposures.
Dose thresholds have also been derived from histologic and radiologic EOIs using the CEM
model. 240 minutes at 43°C has traditionally considered to be a conservative threshold for complete
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coagulation.116 However, many studies have shown a large range for the onset of coagulation and/or
necrosis for doses that are up to an order of magnitude smaller.117–119 This can be explained by
variations in tissue type and the fact that equation 3-14 increases exponentially like equation 3-7.
The CEM model is implemented into one clinical laser ablation systems at with three different dose
thresholds with three dose levels (2,10,60 minutes) the correspond to low, intermediate, and high
thermal doses.8
High uncertainties in the thresholds observed using the CEM model has led at least one
author119 to advocate using the critical temperature model. As previously mentioned in section 3.5,
these applications come almost exclusively from FUS literature since the short duration high
temperature exposures are most appropriate for the CT model. Within a single experiment, the
uncertainty in 𝑇𝑐 is much smaller than the AR or CEM model. However, 𝑇𝑐 values reported across
different studies vary from as low as 48°C-60°C based on modality used and length of
exposure.27,115,119,120
There are several limitations in the way that thermal dose models are applied to ablation
procedures. Both the AR and CEM models rely on model parameters that are derived from
experiments that only approximate biological effects in tissue. The implicit assumption that the
kinetic parameters are similar can be mitigated by empirically determining thresholds for particular
EOIs. However as this method is associated with high uncertainty and can only be considered valid
for the types of experiments that were used to derive the thresholds. Similarly, the CT model
necessarily relies on this empirical analysis. Thus, there is a need for determining model parameters
that are EOIs specific, especially as the number of clinically relevant EOIs expands.
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A Multi-Parametric Pulse Sequence for Thermal Therapy
Monitoring
4.1 Introduction
Clinically utilized imaging EOIs are currently almost exclusively based on post-treatment
imaging. These are usually longer acquisitions which take considerable time to acquire. The current
standard approach for thermal ablation is to identify the region of damaged tissue by administration
of contrast agent in order to assess the regions which have lost perfusion. In section 2.5 the
temperature dependence of several intrinsic MR parameters was reviewed. Consistent with prior
literature, it was demonstrated that these parameters changed linearly with temperature.
However, as tissue is irreversibly damaged, and substantial changes in the chemical environment
alter the rate at which these parameters change with temperature. These changes in linearity have
been widely considered to be a liability in the context of providing an independent means of
temperature monitoring during high temperature thermal ablation therapies. However, when this
information is instead used in conjunction with temperature monitoring, such as from the PRF shift,
there is potential to be used as direct measurement of tissue damage during treatment. Multiparametric pulse sequences that measure multiple temperature sensitive parameters
simultaneously are of interest for direct damage monitoring and for training thermal dose models
because they provide pixel-wise information on tissue temperature and state throughout the entire
procedure. In this chapter, a multi-parametric MR sequence is designed for this purpose. An existing
multi-echo pulse sequence is modified so that the flip angle can be altered in dynamic fashion for
real-time estimates of the PRF, R2*, and T1 during thermal therapy procedures. The modified
sequence is validated against the product pulse sequence and the ability to quantify each of the
parameters is investigated.
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4.2 Methods
4.2.1 Pulse Sequence Design and Validation
The multi-parametric pulse sequence was designed for a clinical 3T MRI scanner (Discovery
750; GE Healthcare Technologies; Waukesha, WI) using the EPIC pulse sequence design
environment. Modifications were made to the product fast gradient-recalled echo (FGRE) source
code, which serves as the basis for a majority of the product 2D gradient echo sequences. This
custom sequence was renamed ‘mfamfgre2d’ (multi-flip angle, multi-echo FGRE 2D) and the pulse
sequence diagram for a single phase utilizing unipolar readout is shown in Figure 4-1.

Figure 4-1: Mfamfgre2d pulse sequence diagram. RF pulse amplitude and gradient waveforms for slice (zgrad),
phase (ygrad), and unipolar frequency (xgrad) encode gradients.
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Although multi-phase (i.e. time points) and multi-echo options are available within the
product FGRE sequence, the source code had to be modified to make both options available
simultaneously. The flip angle was controlled at each acquisition phase by scaling the RF pulse
amplitude using the control variable (CV) ‘ia_rf1’. This CV represents the amplitude of the RF pulse
relative to the value determined during automated tuning of the scanner prior to acquisition (e.g.,
‘prescan’) and has a maximum value of 215-1=32,676. The value of this CV can be written as a
function of the desired flip angle, 𝛼, and the nominal flip angle,𝛼𝑛𝑜𝑚 if the small flip angle
approximation 121holds:
𝑖𝑎_𝑟𝑓1 = 32,767 ∗ 

𝛼

𝛼𝑛𝑜𝑚
Use of the small flip angle approximation limits the application of this sequence to flip

4-1

angles of approximately <30°. However, in this sequence the RF pulse is optimized using a ShinnarLe Roux algorithm122 and so the shape of the RF pulse is automatically changed as the flip angle
changes for SAR and timing purposes. One of the thresholds for transition between different RF
shapes occurs at 30° which provides a practical reason for restricting the available flip angles and
justifies the small flip angle assumption. While higher flip angles may be used, the change in the
shape of the pulse could reduce the accuracy of the calculations.
Two additional CVs were added to allow the operator to control the behavior of the
sequence at the scanner console without recompiling the source code. The first, ‘mfa_mode’,
defines how the flip angle changes with each phase. Three options are available: constant flip angle
(mfa_mode=0), alternating flip angle (mfa_mode=1), and a continuously decreasing flip angle. In the
case of alternating flip angle, an additional CV, ‘mfa_low_flip’, controls the value of the second flip
angle. The dependence of the flip angle on the mfa_mode variable, total number of acquisition
phases, 𝑁𝑝ℎ𝑎𝑠𝑒𝑠 , and current acquisition phase, 𝑛𝑝ℎ𝑎𝑠𝑒 , is given in Table 1.
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Multi-Flip Angle Scheme

mfa_mode

Constant

0

Alternating

1

Continuously Decreasing

2

Flip Angle

𝛼 = 𝛼𝑛𝑜𝑚
𝛼={

𝛼𝑛𝑜𝑚 (𝑛𝑝ℎ𝑎𝑠𝑒 = 𝑜𝑑𝑑)
𝛼𝑛𝑜𝑚 /𝑚𝑓𝑎_𝑙𝑜𝑤_𝑓𝑙𝑖𝑝(𝑛𝑝ℎ𝑎𝑠𝑒 = 𝑒𝑣𝑒𝑛)
𝛼 = 𝛼𝑛𝑜𝑚 (1 −

𝑛𝑝ℎ𝑎𝑠𝑒 − 1
)
𝑁𝑝ℎ𝑎𝑠𝑒𝑠

Table 1: Flip angle control using the mfa_mode control variable

A phantom experiment was designed to validate the performance of the modified FGRE
source code did not have unintended consequences on the pulse sequence. A phantom was
designed containing 8 50 mL centrifuge tubes with different concentrations (0.06-0.42 mM) of
Gadolinium based contrast agent (Omniscan, GE Healthcare Technologies, Waukesha, Wisconsin) in
deionized water. The phantom was placed in a transmit-receive quadrature birdcage head coil and
images were acquired at 5 flip angles using the mfamfgre2d sequence. (FOV=25.6 x 25.6 cm, TR= 50
ms, 8 echoes, TEmin=1.4 ms, ESP=1.7 ms, RBW=390 Hz/pixel, slice thickness=5mm, α=10,15,20,25,30,
Nslices=1). Two nearly identical FGRE scans were acquired sequence by manually scaling ia_rf1
between acquisitions. Only the first echoes were used for analysis due to a slight (.1 ms) discrepancy
in echo spacing. A rectangular ROI was drawn just inside the phantom edges to isolate voxels with
significant signal and assure Gaussian distributed noise. (Figure 4-2). Every voxel within this ROI was
compared using Bland-Altman analysis for the two identical FGRE sequences to identify the baseline
differences caused by noise. A second Bland-Altman analysis was performed to compare the
mfamfgre2d sequence and one of the product FGRE sequences in order to detect any systematic
differences between the sequences.
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Figure 4-2: Phantom setup and ROI used for comparison of mfamfgre2d and FGRE sequences. The ROI was
chosen to contain areas with signal due to the non-Gaussian noise properties at low SNR. Gadolinium
concentrations increase counter-clockwise from bottom right corner. Gadolinium concentrations/T1s: 0.06
mM/1214 ms, 0.07mM/1195ms, 0.08mM/1143ms, 0.11mM/1011ms, 0.15mM/877ms, 0.21mM/731ms,
0.32mM/560ms, 0.42mM/461ms.

4.2.2 Object Oriented Multi-Parametric Post-Processing
An object oriented framework was implemented in the MATLAB (Mathworks, Natick, MA)
environment to facilitate multi-parametric processing of the mfamfgre2d sequence. The primary
design goals were to create self-contained object that reduces the memory use and to streamline
routine processing tasks to make them as fast and flexible as possible. The constructor method loads
DICOM images into the object as native 16-bit integers, which reduces the memory required (4x)
compared with the MATLAB default of double precision. PRF, R2*, signal magnitude, and
temperature were all calculated using the autoregressive moving average (ARMA) approach
developed and investigated by Taylor, et al34 that models the signal as damped exponentials in
complex space. Methods developed were for calculating ARMA coefficients with an ROI in parallel,
simultaneously reducing the required memory and processing time for the most computationally
expensive step. Once the ARMA coefficients are known, the calculation of parameters maps is trivial
from a computational perspective so each map was implemented as a dependent method to further
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reduce the required memory. Additional properties are available to define the options for
processing. For example, when calculating temperature, the temperature sensitivity coefficient and
drift correction ROI are determined from corresponding properties within the object and allows fast
and robust changes to processing. This object oriented framework greatly expedites the multiparametric processing, especially as the number of time-points, echoes, and model order increases.
4.2.3 PRF/T2* Dependence on Flip Angle
Multi-flip angle capability was incorporated into the mfamfgre2d sequence to enable T1
quantification. However, it is important to ensure that this addition does not adversely impact
quantification of the other two parameters of interest: PRF and T2*. A phantom containing 6
centrifuge tubes with different concentrations (0.04-0.62 mM) of Gadolinium based contrast agent
(Omniscan, GE Healthcare, Waukesha, Wisconsin) in deionized water. The phantom was placed in
the T/R quadrature head coil and images were acquired at 12 flip angles using the mfamfgre2d
sequence. (FOV=25.6 x 25.6 cm, TR= 30 ms, 8 echoes, TEmin=1.4 ms, ESP=1.7 ms, RBW=390 Hz/pixel,
slice thickness=5mm, α=2.5°-30° Nslices=1). This sequence was repeated 5 times to get assess the
uncertainty in the signal measurements. Average values of PRF and T2* were measured in a 5x5
pixel ROIs for each repetition and Gadolinium concentration using in the center of each centrifuge
tube. (
Figure 4-3) A one way analysis of variance (ANOVA; α=0.05) was performed for each
concentration to assess whether the any of the mean parameter were significantly different at any
of the flip angles. In cases where a difference was observed, a Tukey-Kramer (α=0.05) multiple
comparison test was used to identify which flip angles were significantly different from one another.
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Figure 4-3: Setup and ROIs for assessing the dependence of PRF and T2* on flip angle. Each centrifuge tube
analyzed contains Gadolinium based contrast agent. Gadolinium concentrations/T1s: 0.04 mM/1303 ms (blue),
0.06 mM/1214 ms (red), 0.10mM/1085 ms (green), 0.16mM/881 ms (black), 0.27mM/633 ms (magenta),
0.62mM/340 ms (cyan).

4.2.4 Temperature Sensitivity Coefficient
A critical component of temperature imaging is validation of the temperature sensitivity
coefficient, 𝛽, that relates changes in the PRF to temperature (equation 2-2). The temperature
sensitivity coefficient was measured in two separate phantom experiments by comparing the
change in PRF with an independent temperature measurement during laser heating. Each phantom
was composed of 50% egg white (Crystal Farms, Minnetonka, MN) and 50% deionized water by
volume mixed with 1.5% agarose (weight/volume) (A0169, Sigma-Aldrich, St. Louis MO) and
Gadolinium based contrast agent (0.06mM/0.21mM; Omniscan, GE Healthcare, Waukesha, WI). A
water-cooled diffusing tip laser fiber (VCLAS-400-12-T10-11, Medtronic Navigation; Louisville,
Colorado) attached to a 980nm diode laser (Photex15, Biotex, Houston, Texas) was inserted into the
phantom. A fluoroptic temperature probe (m3300/STB, Lumasense, Santa Clara CA) was inserted
within a few cm of the diffusing fiber tip. The phantom was exposed a 10 W for 8-9 minutes while
monitored using the mfamfgre2d sequence. (field of view (FOV)=25.6 x 25.6/19.2x19.2 cm, TR= 35
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ms, 8 echoes, minimum echo time (TEmin)=2.5/2.1 ms, echo spacing (ESP)=2.5/2.1 ms, receiver
bandwidth (RBW)=195/325 Hz/pixel, slice thickness=3mm, number of slices =1, α=30,
mfa_mode=1/0, mfa_low_flip=2/2, time between phases=4.8s). The temperature values measured
using the fluoroptic probe were interpolated to match the MRTI temporal resolution. The
temperature sensitivity coefficient and the 95% confidence intervals were calculated using linear
regression (“regress”, MATLAB, Mathworks, Natick, MA) on the PRF values measured using MRTI in
a single pixel at the probe tip and the interpolated fluoroptic probe measurements.

Figure 4-4: Setup and pixels of interest for two temperature sensitivity coefficient measurements in phantom.
The position of the laser fiber and temperature probe are indicated by regions of low signal on magnitude
images. The pixels used for the temperature sensitivity measurements (red) were identified by comparing
images with multiple echo times and using knowledge of how far the temperature probe extended beyond the
introducing catheter.

4.2.5 T1 Quantification
Multiple-flip angle capability was incorporated into the mfamfgre2d sequence for the
purposes of evaluating the quantification of the T1 relaxation time during the MRTI acquisition.
Theoretically, the steady state signal, S, of a spoiled-gradient echo sequence as a function of flip
angle, α, is given by:
𝑆 = 𝑆0

(1 − 𝐸1 ) sin(𝛼)
1 − 𝐸1 cos(𝛼)
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where 𝑆0 is the equilibrium magnetization and 𝐸1 = 𝑒 −𝑇𝑅/𝑇1 . In a multi-flip angle acquisition
𝑇1 can be found using nonlinear regression techniques or by linearizing equation 4-2:
𝑆
𝑆
= 𝐸1
+ 𝑆0 (1 − 𝐸1 )
sin(𝛼)
tan 𝛼

4-3

The number and choice of flip angles for dynamic 𝑇1 mapping must balance the tradeoff
between temporal resolution and the accuracy and precision of the measurement. Several studies
have shown that that high precision can be maintained with only two flip angles provided that
optimal flip angles are chosen.48 However, it should be noted that 𝑇1 accuracy can be biased at low
SNR due to Rician noise properties of the MR signal123. The optimal flip angle pair is given by:124,125
𝛼𝑜𝑝𝑡 = cos −1 (

𝐸1 ± √2(𝐸12 − 1)
)
2 − 𝐸12

4-4

Or alternatively:
𝑆(𝛼𝑜𝑝𝑡 ) = 0.71 × 𝑆(𝛼𝐸 )

4-5

Where 𝑆(𝛼𝑜𝑝𝑡 ) is the signal at the optimal flip and 𝑆(𝛼𝐸 ) is the signal at the Ernst angle
(𝛼𝐸 = cos−1 (𝑒 −𝑇𝑅/𝑇1 )). The values of the optimal flip angles are plotted in Figure 4-5 for
physiologic T1s and range of TRs that are compatible with ablation monitoring.
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Figure 4-5: Optimal flip angle pairs for T1/TR combinations relevant for MRTI monitoring. For a given T1, there
exists a pair of flip angles that optimize the precision of dual flip angle T1 measurements. One flip angle is
higher (dotted) than the Ernst angle (not shown for clarity) and while the other is lower (solid) than the Ernst
angle. T1 values were selected to represent physiologic values in tissue. Limits on TR were chosen to maintain
temporal resolution consistent with ablation procedures (128 phase encode lines x 100 ms = 12.8s per image).

The above discussion of mapping T1 using optimal flip angles ignores the unavoidable
contributions of B1 inhomogeneity caused by spatially varying conductivity and permittivity in the
sample. B1 inhomgeneities cause the actual flip angle to deviate from the nominal flip angle in a
spatially varying manner. Several methods126–130 exist for mapping the B1 field so that equations 4-2
and 4-3 can be fit using the true flip angle at each pixel. In this work we use the Double Angle
Method (DAM)131 for primarily practical purposes as it does not require modification of pulse
sequence source code. In the DAM method two images are acquired at angles 𝛼𝑛𝑜𝑚 and 2𝛼𝑛𝑜𝑚
with a long TR (>5𝑇1 ). After substituting into equation 4-2 and using the double angle formula the
ratio of the two images can be written:
𝛼 = cos−1 (

𝑆(2𝛼𝑛𝑜𝑚 )
)
2𝑆(𝛼𝑛𝑜𝑚 )

4-6

For the case of the mfamfgre2d sequence, slice profile effects significantly alter the
measured signal as a function of flip angle. This is caused by a distribution of flip angles in the slice
select direction. To account for these effects the mfamfgre2d time domain Shinnar-LeRoux (SLR) RF
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pulse was plotted over a variety of flip angles using the WTools (GE Healthcare, Waukesha, WI)
simulation environment and exported to MATLAB (MathWorks, Natick, MA) where it was Fourier
transformed and scaled by the slice select gradient magnitude to convert to physical distance.
Assuming that the slice profile is given by the Fourier Transform of the RF pulse is a reasonable
approximation in the small flip angle regime. A plot of the slice profile as a function of slice thickness
is shown in Figure 4-6. These slice profiles were used to numerically solve for the theoretical signal
response, 𝑆′(𝛼)as a function of the nominal flip angle by integrating equation 4-2 over α.132

Figure 4-6: Mfamfgre2d slice profiles. Slice profiles were calculated by simulating the RF pulse in the WTools
environment, performing a Fourier transform, and scaling by the magnitude of the slice encode gradient. These
profiles assume the simulated RF pulse accurately reflects the true pulse experience by an object being imaged
and that the small flip angle approximation holds

Phantom experiments were designed to evaluate the ability to quantify T1 using the
mfamfgre2d pulse sequence. A phantom containing 8 centrifuge tubes with different concentrations
(0.001-1.215 mM) of Gadolinium based contrast agent diluted in deionized water (Omniscan, GE
Healthcare, Waukesha, Wisconsin). A ninth centrifuge tube was filled with 1:1 deionized water:lard
(Armour, Grand Prairie, TX) mixture mixed with 1.5% agarose (weight/volume) (A0169, SigmaAldrich, St. Louis MO) and 4 lecithin dietary supplements (4.8 mg; CVS Pharmacy, Woonsocket, RI) as
an emulsifier. The phantom was placed in the 32 channel head coil (GE Healthcare, Waukesha,
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Wisconsin) and images were acquired at 12 evenly spaced flip angles using the mfamfgre2d
sequence. (FOV=19.6 x 19.6 cm, 128x128 acquisition matrix TR= 35 ms, 8 echoes, TEmin=1.6, ESP=2
ms, RBW=326 Hz/pixel kHz, slice thickness=5mm, α=2.5°-30°). The B1 field was mapped using a 12
flip angle mfamfgre2d (FOV=19.6 x 19.6 cm, 64x64 acquisition matrix, TR= 6,000 ms, 8 echoes,
TEmin=1.6, ESP=1.3 ms, RBW=326 Hz/pixel kHz, slice thickness=5mm, α=2.5°-30°). All T1 related
measurements used the first echo only. Gold standard T1 measurements for comparison were made
using an multi-inversion time fast spin echo (FSE) (FOV=19.6 x 19.6 cm, 256x256 acquisition matrix,
TR= 4000 ms, ETL=4, TE=8.3, RBW=244 Hz/pixel kHz, slice thickness=5mm,
TIs=50,75,100,150,250,500,750,1000,1500, 2000, 2500 ms) and fit using the IR signal equation:
𝑆 = 𝑆0 (1 + 𝑒 𝑇𝑅/𝑇1 − 2𝑒 −𝑇𝐼/𝑇1 )

4-7

For each sequence and concentration the signal was averaged over a 9x9 ROI for analysis
(Figure 4-7).

Figure 4-7: T1 quantification phantom and ROIs. Concentrations/T1s:1.2150 mM (blue), 0.6075 mM (red),
0.3038 mM (green), 0.1519 mM (magenta), 0.0759 mM (cyan), 0.0380 mM (white), 0.0190 mM (yellow),
0.0095 (orange)
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The DAM method for B1 mapping also suffers from slice profile effects so the two sources of
error cannot be corrected independently. A modified version of the technique described by Hsu133
was used to correct for each effect simultaneously. Using this relationship a 5 step procedure was
̃ 133
used to estimate T1 from the measured signal, 𝑆̃
𝑇1 and the measured DAM signal, 𝑆𝐷𝐴𝑀 :
1. Derive an expression for the flip angle at the center of the slice profile, 𝛼𝑐𝑒𝑛𝑡 , as a
function of the observed flip angle, 𝛼𝑜𝑏𝑠 , by simulating the DAM acquisition using
𝑆′(𝛼𝑐𝑒𝑛𝑡 ) and calculating 𝛼𝑜𝑏𝑠 using equation 4-6.
2. Calculate 𝛼𝑐𝑒𝑛𝑡 for each DAM pair in 𝑆̃
𝐷𝐴𝑀 using equation 4-6 and𝛼𝑐𝑒𝑛𝑡 (𝛼𝑜𝑏𝑠 ).
3. Estimate 𝑇1 by fitting 𝛼𝑐𝑒𝑛𝑡 vs. 𝑆̃
𝑇1 using equation 4-2
4. Using the 𝑇1 calculated in 3, calculate the theoretical ratio, 𝑘, between the observed
signal 𝑆′(𝛼𝑐𝑒𝑛𝑡 )/𝑆(𝛼𝑐𝑒𝑛𝑡 )
5. Divide 𝑆̃
𝑇1 by 𝑘 to get 𝑆𝑇1 ’, the signal one would observe in the absence of slice
profile effects.
6. Iterate through steps 3-5 while replacing 𝑆̃
𝑇1 with 𝑆𝑇1 ’ in step 3 but not step 4 (5
iterations)
The T1 values recovered using this iterative approach are compared to two other
approaches for reference: a direct fit of 𝑆̃
𝑇1 using 4-2 (ignore B1 effects and slice profile effects) and
a direct fit of 𝑆̃
𝑇1 using 𝑆′(𝛼𝑐𝑒𝑛𝑡 ) (ignore B1 effects).

4.3 Results
4.3.1 Pulse Sequence Design and Validation
The pulse sequence modifications were successfully implemented and run on the GE MR750
scanner for 4 different software versions (DV23, DV24, DV25, DV2R2). The Bland-Altman comparison
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between the signal magnitudes of the two FGRE scans is shown in Figure 4-8. The difference
between the two scans appears to be independent of the mean signal value and there is a
statistically significant (p<.01) mean difference of 0.3 AU with a 95% confidence interval from -29 to
28 AU. The same comparison is made between the FGRE sequence and mfamfgre2d sequence in
Figure 4-9. The mean difference is 0.054 AU and the 95% confidence interval ranges from -32 to 32
AU. In this case there is a slight but visible increase in the difference over a range approximately 750
to 1250 AU. Although these mean differences are statistically significant in both cases they are
inconsequential compared to the median signal value (≈1100 AU) and when the integer nature of
the signal magnitude is considered. There is a 7 AU increase in the 95% confidence interval when the
FGRE and which is also small compared to the median signal value. This is most likely caused by the
increase in the differences from 750-1250 AU, which is likely local in nature given its mean signal
dependence. This could be caused by minor alterations in the phantom that occurred between the
two scans (e.g. air bubble, motion) and is consistent with the timing of when the scans were
acquired (≈15 minutes between mfamfgre2d and FGRE vs. 3 minutes between FGRE and FGRE).

Figure 4-8: Bland-Altman comparison of signal values obtained using two identical FGRE sequences.

43

Figure 4-9: Bland-Altman comparison of signal values obtained using mfamfgre2d and FGRE sequences.

4.3.2 PRF/T2* Dependence
Representative examples of the PRF and T2* dependence on flip angle are shown in Figure
4-8 and Figure 4-9 and the p-values from the 1 way ANOVA are tabulated in Table 2. For PRF, no
significant change with flip angle is observed with the exception of the 0.04 mM concentration. For
T2*, a significant change with flip angle was detected at all concentrations except 0.06 mM and 0.62
mM. In each of these cases the Tukey-Kramer multi-comparison test reveals that the significant
difference is only found at the lowest two flip angles (2.5°/5°) which suggests that the differences
are SNR dependent rather than caused by alterations to the pulse sequence. Coincidentally, the only
significant difference observed in the PRF measurements was found at the highest T1 and close to
the edge of the coil, further supporting the difference is an SNR effect rather than a pulse sequence
effect.
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Figure 4-10: Representative comparison of PRF±2σ (A) and T2*±2σ (B) as a function of flip angle. Flip angles
with significantly different means are denoted by and asterisk (Concentration 0.06 mM; T1=1214 ms).

T1 (ms)
Concentration (mM)

1303
0.04

1214
0.06

1085
0.10

PRF
T2*

<0.01* 1.00 1.00
<0.01* 0.01* 0.02

881
0.16

633
0.27

340
0.62

0.99
0.99
1.00
<0.01* <0.01* 0.90

Table 2: P-Values from ANOVA comparison of T2* and PRF values for each Gadolinium concentration. (p<0.01
bolded and with asterisk)

4.3.3 Temperature Sensitivity
The measured value of the temperature sensitivity coefficient and 95% confidence intervals
were -0.0103(-0.0105-0.0101) and -0.0110(-0.0113-0.0106) which are consistent with the expected
value -0.01 ppm/°C and the previous results measured by Taylor for the same sequence and postprocessing technique. (Figure 4-11)134
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Figure 4-11: Example of temperature sensitivity coefficient measurement. A linear regression is performed
between the temperature measurement made using a fluoroptic probe and the PRF values measured using
MRTI.

4.3.4 T1 Quantification
The theoretical relationship 𝛼𝑐𝑒𝑛𝑡 (𝛼𝑜𝑏𝑠 ) for the mfamfgre2d sequence is plotted as
function of the observed flip angle in Figure 4-10. The center flip angle is always greater than the
observed flip angle and the deviation increases with the observed flip angle. This trend is closest to
the results of Hsu133 for a Hamming windowed 4-lobe sinc pulse. However, the magnitude of the
difference is increased. This is not entirely unexpected because the mfamfgre2d pulse is
approximately Gaussian and deviates from the ideal slice profile more than a truncated sinc pulse.
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Figure 4-12: Center flip angle as a function of the observed flip angle measured using the DAM method. The
relationship between the center flip angle and observed flip angle (red) is calculated by simulating the DAM
experiment using 𝑆′(𝛼). The line of unity (black dotted) is plotted for reference. This relationship can
theoretically correct the observed flip angles using the DAM method for slice profile effects.

The results in Figure 4-10 were applied to the DAM acquisition to obtain the 𝛼𝑐𝑒𝑛𝑡 for each
flip angle pair and Gadolinium concentration and is expressed as a ratio 𝛼𝑐𝑒𝑛𝑡 /𝛼𝑛𝑜𝑚 (Figure 4-13)

Figure 4-13: Center flip angle as a function of nominal flip angle for each Gadolinium concentration.
Concentrations/T1s: 1.2150 mM (blue), 0.6075 mM (red), 0.3038 mM (orange), 0.1519 mM (purple), 0.0759
mM (green), 0.0380 mM (cyan), 0.0190 mM (maroon), 0.0095 (blue)
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The measured center flip angle increases drastically at low flip angles to unrealistically high
values. This is consistent with the contribution of the inherent bias in MR signal increasing at low flip
angles. For this reason the center flip angles were scaled by the measured at 15° as this is the most
reliable measurement. The flip angle ratios were 2.00, 1.94, 1.8, 1.85 1.82, 1.61 1.58, 1.60 for
concentrations of 1.2150, 0.6075, 0.3038, 0.1519, 0.0759, 0.0380, 0.0190, 0.0095, respectively.
When these flip angles the used to correct the signal the corrected values are far lower than the
values measured using inversion recovery and had a minimum difference of approximately 100ms.
(Figure 4-14) If no correction is made, a similar underestimation of T1 is observed (Figure 4-15)

Figure 4-14: T1 measurement using iterative method for simultaneous B1 and slice profile correction.T1 values
measured using inversion recovery (±95% confidence interval) compared to multi-flip angle method.
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Figure 4-15: T1 measurement without B1 or flip angle correction. T1 values measured using inversion recovery
(±95% confidence interval; blue) compared to multi-flip angle method (±95% confidence interval; red).

4.4 Discussion
In this chapter a multi-parametric pulse sequence for thermal therapy monitoring was
successfully implemented on a clinical 3T MRI. This sequence is effectively equivalent to the product
pulse sequence when the directly compared using the same scan parameters. A scheme for altering
the flip angle via scaling the amplitude of the RF pulse was added for dynamic measurement of T1.
This addition has no discernable impact on the quantification of T2* or PRF outside of SNR effects
observed at low flip angles. Measurements of the temperature sensitivity coefficient are also
consistent with expected values.
Quantification of T1 is complicated by several constraints. MFA measurements are
effectively restricted to flip angles under 30° due to the practical limitations in the pulse sequence
design. The impact of this can be understood by examining Figure 4-5. The Ernst angle is always in
between the optimal flip angle pair and remains under 35° over the entire T1/TR range in the figure.
The high flip angle rapidly exceeds the 30° limit of the mfamfgre2d sequence. However, Schabel et
al.125 have shown that the precision is relatively insensitive to the value of the higher flip angle
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compared to low flip angle for TRs in this range. Thus, in the case where 4-2 holds, the limited range
of flip angles is suboptimal but it can be worked around through careful selection of sequence
parameters.
Two factors that have a larger impact on T1 quantification in the mfamfgre2d sequence are
the effects of B1 inhomogeneity and the slice profile. An iterative method that accounts for both
effects simultaneously was tested against gold standard inversion recovery method. The corrected
T1 values remained substantially lower than the true values and showed no discernible
improvement over the uncorrected values (Figure 4-15). It is difficult to isolate where this correction
fails as both effects are convolved with one another. However, Figure 4-13 provides some insight
into the appropriateness of the correction for B1 inhomogeneity. The measurement is clearly biased
at small flip angles but the B1 inhomogeneity at the highest flip angle is still approximately double
the nominal value. Although localized deviations of this magnitude have been measured using the
DAM135, they are not expected to cover a region that contains the centrifuge tubes . Even if this
measurement is assumed to be accurate it implies that the flip angle far exceeds the 30° limit and
the small flip angle approximation is violated.
Several options exist for rectifying the inability to obtain accurate T1 values. Perhaps the
most straightforward approach is to make similar alterations to 3D spoiled gradient echo sequence.
This would eliminate slice profile effects and allow B1 effects to be isolated. Far shorter TRs would
result in in lower optimal flip angles and certainly justify the small flip angle approximation and the
same amplitude scaling scheme. The primary draw back to using a 3D sequence is the additional
time required to phase encode in the z-direction to prevent aliasing. While this could be mitigated
by using some combination of parallel imaging, view sharing, and saturation bands, the impact on
temporal resolution would need to be carefully considered on a case by case basis. Implementing a
B1 mapping method that is less sensitive to slice profile effects, such as the Bloch-Siegert130
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technique, would also aid in deconvolving the two sources of uncertainty with reduced scan time.
Greater control over the RF pulse shape would also be advantageous as it would allow systematic
examination of impact of the slice profile, including pulses that are far closer to the ideal rectangular
slice profile. Techniques that use look-up tables are also available136 but require acquisition of large
amounts of data before experiments and rely on the assumption that the B1 field does not change
significantly when different objects are scanned.
These results are best viewed in comparison to other studies in the literature examining
hyrbrid PRF/T1 technique for temperature monitoring. Hey et al.50 used a similar approach with a 2D
acquisition. The primary difference was the use of high specific bandwidth sinc-Gaussian pulse137 to
obtain a more rectangular profile. The increase in SAR was offset somewhat an EPI readout which is
not compatible with the multi echo acquisition. Todd et al.32,138 used an almost identical sequence
where all flip angles were scaled using a calibration factor calculated from inversion recovery
experiments. However, their approach was intended primarily to supplement the PRF method in
breast adipose tissue. It was successful in this respect but still suffered similar underestimation was
in pork muscle due to its longer T1 (≈900 ms). This is consistent with the results presented here of
decreasing error with T1.
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Development of a Methodology for Fitting Thermal Dose
Models Using Magnetic Resonance Imaging
5.1 Introduction
One of the primary barriers to fitting thermal dose models to clinical ablation data is the
underlying mathematics associated with applying the model in the face of a dynamically changing
temperature. Equations 3-7 and 3-12 are transcendental and impossible to solve analytically for the
case of an arbitrary temperature history. Consequently, thermal dose models have traditionally
been derived from laboratory experiments where the temperature is precisely controlled and the
integrals can be solved analytically. This requirement is practically impossible to adapt to clinical
procedures where spatial and temporal temperature gradients are unavoidable. An additional
drawback of dose models based on Arrhenius kinetics is that they predict continuous dose values
which are poorly suited for the categorical EOIs that are often observed in the clinic. In this chapter
a novel methodology for solving the AR model parameters is proposed and validated. The proposed
technique relies on solely MRI to acquire the necessary information on both the temperature and
state of tissue. A logistic model is coupled to the AR model to better account for categorical EOI and
nonlinear optimization techniques are used to overcome the transcendental nature of the governing
equations. The overall methodology is first described in a general sense and subsequently validated
in an egg white phantom using intra-treatment and post-treatment changes observed on MRI as
EOIs. Egg white was chosen because it is readily available and is known to be predominantly made
up of proteins whose kinetics closely match the underlying assumptions of the Arrhenius model.
Both models are compared to the Arrhenius parameters in the literature and the region of protein
coagulation observed on a post-treatment T1 which acts as surrogate for visible coagulation.
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5.2 Methods
5.2.1 Model Definition
The AR model is explicitly chosen for model fitting because it relies on the fewest simplifying
assumptions and CEM and CT model parameters can be approximated by the Arrhenius parameters,
𝐸𝑎 and 𝐴. As mentioned in section 3.3.2 the quantitative nature of the AR model is ideal if the
corresponding EOI is quantitative but is problematic for categorical EOIs which need to be arbitrarily
assigned a particular value of Ω or 𝐹𝐶. Many radiologic isoeffects are categorical so this deficiency
needs to be considered in any dose fitting methodology. This is addressed by coupling the
traditional Arrhenius model to a second model that predicts the EOI as a function of 𝐹𝐶. In this work
we consider binary categorical EOIs so a binary logistic model is used. In this case, temperature
histories are assigned a binary classification (𝑦 ∈ {0,1}) that reflects the EOI.
𝑦̂(FC; 𝑘50 , FC50 ) =

1
1 + exp(−𝑘50 (FC − FC50 ))

5-1

This coupled model can be interpreted as predicting the probability of observing an binary
EOI as a function of thermal dose. Instead of assigning an EOI to an arbitrary thermal dose value an
optimal dose threshold can be found that best classifies pixels or represents a probability of interest.
Theoretically, this approach can be generalized to arbitrary models depending on the effect of
interest (e.g. clustering, multinomial logistic regression etc.)
5.2.2 Arrhenius Parameter Optimization
Optimizing the multi-level model in the previous section is not trivial due to the
transcendental nature of the Arrhenius equation. The optimal Arrhenius parameters were defined
to be the pair of 𝐸𝑎 and 𝐴 values that maximize the joint log likelihood,𝑙𝑜𝑔(ℒ(𝐸𝑎 , 𝐴|𝑦)), of the
logistic model in equation 5-1:
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𝑁𝑝𝑖𝑥𝑒𝑙𝑠

𝑙𝑜𝑔(ℒ(𝐸𝑎 , log(𝐴) , |𝑦)) = ∑ 𝑦𝑖 𝑙𝑜𝑔(𝑦̂𝑖 ) + (1 − 𝑦𝑖 )𝑙𝑜𝑔(1 − 𝑦̂𝑖 )

5-2

𝑖=1

The Arrhenius parameters are known to be correlated (see section 3.3.2) over a wide range
of biological processes which further complicates the fitting of dose models. Regardless of whether
this correlation is a consequence of a thermodynamic compensation law or an artefact of the fitting
process139–143, it restricts the possible parameter pairs in the 𝐸𝑎 /𝑙𝑜𝑔(𝐴) parameter space to a line
within some experimental tolerance. A reparametrized expression for the reaction rate, 𝑘, was used
during the optimizations:
𝑘 = exp(𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 ) −

𝐸𝐴 1
1
( −
))
𝑅 𝑇 𝑇𝑅𝑒𝑓

5-3

𝐸𝐴
𝑅𝑇𝑅𝑒𝑓

5-4

where
𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 ) ≡ 𝑙𝑜𝑔(𝐴) −

and 𝑇𝑅𝑒𝑓 was chosen to be equal to 316.5°K to remove the correlation in equation 3-10. This
new 𝐸𝑎 /𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 ) parameter space effectively focuses the parameter search on values near the
line in equation3-10 while facilitating the convergence of the optimization algorithm and aiding in
visualizing the solution144,145. This method of optimization is analogous to the method of Qin et al. 108
with a different objective function and no explicit constraints on the parameter values. The
optimizations were solved using a Quasi-Newton BFGS algorithm (fminunc, MATALB, Mathworks,
Natick, MA) with the Arrhenius parameters reported by Henriques97 as the initial guess. The
approximate Hessian at the solution was inverted to estimate the covariance matrix and generate
confidence ellipses for the parameter values. The solutions and covariance matrices were then
transformed into the traditional 𝐸𝑎 /𝑙𝑜𝑔(𝐴) parameter space for comparison with parameters found
in the literature.
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5.2.3 Egg White Phantom Preparation and Laser Exposure
Egg white phantoms were created using a mixture of 50% egg white (Crystal Farms,
Minnetonka, MN) and 50% deionized water by volume mixed with 1.5% agarose (weight/volume)
(A0169, Sigma-Aldrich, St. Louis MO) and Gadolinium based contrast agent (0.06mM-0.21mM;
Omniscan, GE Healthcare, Waukesha, WI). Thermal lesions (N=17) were created using a watercooled diffusing tip laser fiber (VCLAS-400-12-T10-11, Medtronic Navigation; Louisville, Colorado)
attached to a 980nm diode laser (Photex15, Biotex, Houston, Texas). The applied power and time
was varied from 7-15W for 3-13 minutes with the intention of maximizing lesion size, preventing
melting of the agarose, and sampling a variety of temperature histories. The temperature was
independently measured within a few cm of the diffusing fiber tip using a fluoroptic temperature
probe (m3300/STB, Lumasense, Santa Clara CA).
Multi-parametric monitoring was performed using the mfamfgre2d sequence (FOV=19.2 x
19.2 - 19.6 x 19.6 cm, 128x128 acquisition matrix, TR= 35-100 ms, 8 echoes, TEmin=1.8-2.1 ms,
ESP=2.1-1.8 ms, RBW=195-326 Hz/pixel, slice thickness=3mm, α=25-30°C, mfa_mode=0/1,
mfa_low_flip=2, number of slices=1-3, time between images=4.8-12.4s) on a clinical 3T MRI scanner
(Discovery 750; GE Healthcare Technologies; Waukesha, WI). All slices placed along the long axis of
the laser fiber (coronal). Temperature was calculated using the PRF estimates provided by the ARMA
model and a temperature sensitivity coefficient of -0.01ppm/°C while the apparent temperature
increase caused by drift in the main magnetic field was accounted for by placing an ROI far away
from heating or in an attached centrifuge tube filled with vegetable oil.
After each laser exposure a T1 map was acquired using a multi inversion time fast spin echo.
((FOV=19.2 x 19.2 - 19.6 x 19.6 cm, 256x256 acquisition matrix, TR= 4000 ms, Echo train length=4,
TE=8.3, RBW=244 Hz/pixel kHz, slice thickness=5mm, inversion times(TIs)=100-1200 ms)). A semiautomatic segmentation procedure was performed to determine the extent of the coagulated area
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on post-treatment imaging. Heavily filtered (wiener filter; 10x10 kernel) T1 maps were subtracted
from lightly filtered images (wiener filter; 3x3 kernel) to represent the increase in T1 compared to
background. These maps were thresholded at 10% of the maximum value and used as a starting
point for manual segmentation of the coagulated area. Manual segmentation was necessary
primarily to account for artifacts caused by the presence of the laser fiber. After the experiments the
phantoms were sliced along the axis of the laser fiber to best approximate the MR slice position and
the size of the coagulated area was measured in two dimensions using a ruler.
The exposures are divided into three groups based on differences in scan parameters and
how they were used during post-processing. The alternating flip angle scheme was used for the first
three exposures (group A) but was abandoned in in favor of increased SNR and temporal resolution
when it was observed that the T1-W signal was a sufficient surrogate for identifying an intratreatment EOI. The group A exposures and the subsequent 8 exposures (group B) were determined
to have experienced significant melting over the course of heating. This manifests as a large scale
susceptibility artifact that corrupts temperature imaging in the region of interest. For this reason the
thermal exposure cannot be directly compared to post-treatment imaging. However, the intratreatment EOIs were observed at approximately 60°C so these temperature histories were reserved
for training the intra-treatment models. The final group (group C) was intended to serve as a
validation cohort for the intra-treatment model trained on groups A and B. T1-Weighting was less
critical in this group so the number of slices was increased at the expense of longer TR. The specific
variations between scan parameters and power for each exposure is tabulated in Appendix 1 for
reference.
5.2.4 Intra-Treatment Arrhenius Models
Arrhenius models were investigated for intra-treatment EOIs based the T1-W signal and T2*
measured during each exposure. Both parameters exhibited temperature dependence that changed
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abruptly at one or more breakpoints (i.e. the second derivative became nonzero). In both cases, the
models were trained on breakpoints closest to 60°C that are consistent with those observed in ex
vivo studies.44,14643. For each exposure, all pixels whose temperature exceeded 65°C were isolated
for analysis. The signals were observed to be approximately linear on either side of the breakpoint
and a temperatures were only considered in the range from 40°C-80⁰C to minimize the contribution
of other nonlinearities not associated with the EOI. The T1-W signal was normalized to its
preheating value and a constrained piecewise linear fit was used to identify this breakpoint on a
pixel by pixel basis (fmincon, MATLAB, MathWorks, Natick MA).
This 4 parameter fit is given by:
𝑎𝑟𝑔 𝑚𝑖𝑛 ‖𝐶1 + 𝐶2 𝑇 + 𝐶3 (𝑇 − 𝐵𝑃)𝑠𝑔𝑛(𝐵𝑃) − 𝑆(𝑇)‖2

𝐶1 ,𝐶2 ,𝐶3 ,𝐵𝑃

𝑠. 𝑡. 𝐶1 ∈ [0,2]
𝑠. 𝑡. 𝐶2 ∈ [−∞, 0]
𝑠. 𝑡. 𝐶3 ∈ [−∞, 0]
𝑠. 𝑡. 𝐵𝑃 ∈ [min(𝑇) , max(𝑇)]

5-5

where 𝐶1−3 are constants, 𝐵𝑃 is the breakpoint, 𝑇 is the temperature, and 𝑆(𝑇) is the
relative change in the T1-W signal magnitude. A representative example of this fit is shown in figure
5-4.
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Figure 5-1: Representative example of piecewise linear fit used to for the intra-treatment Arrhenius model. The
breakpoint where the temperature dependence of the normalized T1-W signal changes abruptly is used to
classify temperature histories according to equation 5-8.

A similar approach was used for finding the breakpoints in T2*. However, visual inspection
of the data showed the behavior of the T2* temperature dependence was not as consistent as the
T1-W signal. For example, the magnitude of the slope of the temperature dependence varied from
positive to negative between pixels which required modification of the optimization constraints:
𝑎𝑟𝑔 𝑚𝑖𝑛 ‖𝐶1 + 𝐶2 𝑇 + 𝐶3 (𝑇 − 𝐵𝑃)𝑠𝑔𝑛(𝐵𝑃) − 𝑇2∗ (𝑇)‖2

𝐶1 ,𝐶2 ,𝐶3 ,𝐵𝑃

𝑠. 𝑡. 𝐶1 ∈ [0,2]
𝑠. 𝑡. 𝐶2 ∈ [−∞, 0]
𝑠. 𝑡. 𝐶3 ∈ [−∞, 0]
𝑠. 𝑡. 𝐵𝑃 ∈ [min(𝑇) , max(𝑇)]

5-6

Where 𝑇2∗ (𝑇) is the measured T2* as a function of temperature. Breakpoints were also not
consistently observed in every pixel. To exclude these data from analysis in an automated manner
the Akaike information criterion (AIC)147 was calculated for each piecewise linear fit. For a least
squares model the AIC is defined as:
𝐴𝐼𝐶 = 2𝑘 + 𝑁𝑙𝑜𝑔(𝑅𝑆𝑆)
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Where k is the number of model parameters, N is the number of data points, and RSS is the
residual sum of squares. This AIC is a measure of the quality of a model that penalizes for the
number of model parameters to prevent overfitting. Data were excluded if the AIC values from the
piecewise linear fit were larger than the values calculated for a traditional linear least squares fit.
Examples of a temperature history that were included and excluded not excluded using the AIC
criteria are shown in Figure 5-2. This rejection criteria was also applied to the intra-treatment model
based on T1-w signal.
Once the breakpoints were determined they were used to make two binary classifications:
𝑇(𝐵𝑃 − 2.5℃) → 𝑦 = 0
5-8
𝑇(𝐵𝑃 + 2.5℃) → 𝑦 = 1
Where the 2.5℃ is added to account for uncertainty in the breakpoint and the temperature
imaging. This is particularly important at low heating rates where the precise time the breakpoint
was reached is not known with high precision. After applying AIC rejection criteria both models were
fit using the optimization scheme outlined in section 5.2.1.
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Figure 5-2: Example of breakpoint determination for the T2* intra-treatment Arrhenius model. The existence of
a breakpoint was determined by comparing AIC values between the piecewise linear fit (solid) and a traditional
linear fit (dotted). A break point was observed in A but not B.

5.2.5 Post-Treatment Arrhenius Model
A third model was trained using post-treatment increases in T1 as a post-treatment
isoeffect. Temperature histories associated with increases in T1 using the method described in in
section 5.2.3 were assigned values of 𝑦 = 1. This region was dilated using a 5x5 kernel (≈5mm). Any
unassigned pixels within this larger region were assigned values of 𝑦 = 0. A representative example
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of these ROIS is shown in Figure 5-3. This model was only trained using exposures in group C only
due to the previously measured susceptibility artifacts. (Total number of pixels = 3,956)

Figure 5-3: ROIs used for post-treatment model. The inner region represents the region of T1 increase (y=1)
while the surrounding region represents pixels that were exposed to elevated temperatures without any T1
increase (y=0).

5.2.6 Model Comparisons
The Arrhenius parameters were directly compared to values found in the literature for
protein denaturation measured using dynamic scanning calorimetry (DSC) and turbidity measured
using spectrophotometer. References were restricted to those examine whole egg white148,149 rather
than isolated constituent proteins, such as ovalbumin150,151. Unfortunately, independent
measurements of the frequency factor are not available and they had to be estimated using 3-10.
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Log Frequency Factor,

Activation Energy, 𝐸𝐴

Effect of Interest (EOI)

log(𝐴)

[kJ/mol]

Note

Denaturation148,149

157

439

pH 7.6149

136

383

pH 8.8149

135

380

pH 7.6148

87

254

pH 7.6149

85

248

pH 7.6148

Turbidity148,149

*Estimated using equation 3-10
Table 3: Selected literature values for egg white

The model predicted regions, 𝐴𝑚𝑜𝑑𝑒𝑙 , were calculated for each ablation and compared to
the segmented regions,𝐴𝑠𝑒𝑔 , found on post-treatment T1 mapping to get a practical measure of the
goodness of fit using three methods of comparison. The first is the Dice Similarity Coefficient (DSC):
𝐷𝑆𝐶 =

2|𝐴𝑚𝑜𝑑𝑒𝑙 ∩ 𝐴𝑠𝑒𝑔. |
|𝐴𝑚𝑜𝑑𝑒𝑙 | + |𝐴𝑠𝑒𝑔. |

5-9

The DSC is a measure of the spatial overlap of two regions where a value of 1 corresponds to
complete overlap and a value of 0 corresponds to no overlap. While the DSC is commonly used in
radiology research, its value is biased by the center of the lesion which is virtually guaranteed to
match assuming the areas are properly registered. For this reason, two additional quantities of
interest based on the distances between the model and segmentation boundaries were used. In
general, for two boundaries defined as sets of Cartesian coordinates, 𝐴 = {𝑎1 … 𝑎𝑛 } and 𝐵 =
{𝑏1 … 𝑏𝑚 }, the quantity 𝑑(𝐴, 𝐵):
𝑑(𝐴, 𝐵) = min{‖𝑎 − 𝑏‖2 }
𝑏∈𝐵

62

5-10

represents the minimum Euclidean distance from between every point on boundary A and
any point on boundary B. Note that 𝑑(𝐴, 𝐵) is not communitive (𝑑(𝐴, 𝐵) ≠ 𝑑(𝐵, 𝐴)). Model and
segmentation boundaries were compared using the Hausdorff Distance (HD):
𝐻𝐷(𝐴, 𝐵) = max {max 𝑑(𝐴, 𝐵) , max{𝑑(𝐵, 𝐴)}}
𝑎∈𝐴

𝑏∈𝐵

5-11

Which is the maximum value of 𝑑 found in 𝑑(𝐴, 𝐵) and 𝑑(𝐵, 𝐴). This is a common measure
of agreement between two sets because it is a metric in the formal sense and can be interpreted as
the worst case disagreement between the two contours. However, as a maximum value it is
inherently sensitive to noise and outliers. For this reason the average difference between the
boundaries or mean distance to agreement (MDA):
𝑀𝐷𝐴(𝐴, 𝐵) =

∑𝑛𝑖=1 𝑑(𝐴, 𝐵) + ∑𝑚
𝑖=1 𝑑(𝐵, 𝐴)
𝑚+𝑛

5-12

was also used to compare the radiologic feature models to the inner and outer boundary
segmentations. Taken together these three methods give a more complete picture of model
performance. The value of each of these metrics was averaged over the 3 slices for each exposure in
group C and are given in Table 6 and Table 7.

5.3 Results
Each exposure resulted in a coagulated regions that could be identified visually and on T1weighted imaging. The upper limit on lesion size while preventing melting in the agarose gel was
approximately 1.1 cm. Excellent agreement was observed between the lesions measured visually
and the regions segmented on post-treatment imaging in group C. The maximum difference was 1
mm which is small considering the uncertainties associated with precisely cutting the phantom,
partial voluming, and the pixel size of 0.75mm. Thus, the post-treatment changes in T1 were
considered surrogates for visible coagulation when evaluating the fitted models.

63

The post-treatment and intra-treatment T1 models converged to unique solutions that are
plotted in the 𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 )/𝐸𝐴 parameter space in Figure 5-4a-b. Both solutions are plotted together
in the traditional 𝑙𝑜𝑔(𝐴)/𝐸𝐴 reference space in Figure 5-4c. The advantage of the
reparameterization in equations 5-3 with respect to visualizing the solutions are obvious by
comparing these two figures. The activation energies associated with the 95% confidence intervals
ranged from 342-470 kJ/mol and 257-344 kJ/mol for the intra-treatment and post-treatment
models, respectively. Although the solutions are close to one another and the objective function
surfaces are similar, their confidence ellipses do not overlap. However, they do cover the range of
activation energies found in the literature. The complete set of parameters that define these
confidence intervals along with 𝑅𝐶𝐸𝑀 and 𝑇𝐶 ′ calculated using equations 3-13 and 3-16 are found in
Table 4. The intra-treatment model using T2* as an EOI did not converge to a unique solution within
the range of physically realistic values (Figure 5-2). Significantly more pixels were rejected for this
EOI (29%) compared to the T1-W intra-treatment EOI (6%).
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Figure 5-4: Optimal Arrhenius parameters for the intra- and post-treatment models (T1-W signal and ΔT1). The
optimal Arrhenius parameters (green circle) and 95% confidence regions (green) are shown with the negative
log likelihood in the background in the 𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 ) /𝐸𝐴 parameter space for the intra treatment (A) and posttreatment dose (B) models. The same data is shown in the 𝑙𝑜𝑔(𝐴) /𝐸𝐴 parameter space (C) where the intratreatment model is plotted in green and the intra-treatment model is plotted in red. Selected Arrhenius
parameters from the literature (magenta) for egg white are plotted using denaturation (●) and turbidity (▲)
as EOIs.
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Intra-treatment (T1-w)

Post-treatment (T1)

Activation Energy, 𝐸𝐴 [kJ/mol]

405

301

Log Frequency Factor, log(𝐴) [s-1]

142

103

Minor axis length

0.225

0.197

Major axis length

68.1

45.9

Slope [kJ-1]

0.364

0.365

Intercept

-4.71

-6.15

𝑅𝐶𝐸𝑀

0.62

0.70

𝑇𝐶 ′ [°C]

68

74

Table 4: Optimal Model Parameters and 95% Confidence Ellipse for intra-treatment and post-treatment
models.

Figure 5-5: Objective function surface for intra-treatment T2* model. The optimization does not converge to a
solution. Selected Arrhenius parameters from the literature (magenta) for egg white are plotted using
denaturation (●) and turbidity (▲) as EOIs.

The optimal dose thresholds were found to be 𝐹𝐶 = 0.53 and 𝐹𝐶 = 0.40 for the intratreatment and post-treatment model, respectively (Table 5). Plots of these optimal dose thresholds
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are shown in Figure 5-6 along with the false positive and true negative rates for reference. The area
under curve (AUC) and accuracy were 0.92/88% and 0.93/86% and for the intra-treatment and posttreatment model, respectively. The model predicted regions were compared with the segmented
regions for each exposure in group C and a representative example of the contours is shown in
Figure 5-7. Qualitative comparison shows good agreement between the model predicted and
segmented regions and very little difference between the two dose models. This is confirmed using
the three metrics with DSC/HD/MDA of 0.82/2.84 mm/0.98 mm and 0.83/2.72 mm/0.92 mm for the
intra-treatment and post-treatment isoeffects, respectively. (Table 6 and Table 7)

Intra-Treatment

Post-Treatment

𝒌

6.35

7.1

𝑭𝑪𝟓𝟎

0.53

0.40

̂/𝑭𝑪/𝜴) 0.53/0.54/0.78
AR Model Thresholds (𝒚

0.45/0.40/0.51

Table 5: Optimal dose thresholds for intra-treatment and post-treatment isoeffect
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Figure 5-6: Logistic model results for intra- and post-treatment models. The logistic model prediction (black
solid) ± 95% confidence intervals (black dotted) for the intra-(A) and post-treatment(B) dose models with false
positive rate (blue) and true negative rate (red). The thresholds that optimize the accuracy are shown cyan.

Figure 5-7: Comparison between segmented regions and predicted dose for intra-treatment and posttreatment models. The segmented regions (red) and the predicted dose (green) are shown for all three slices
the intra-treatment (A-C) and post-treatment models (D-F). Magenta arrows identify subtle differences
between the predicted dose contours from each model.
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Exposure #

DSC

HD (mm)

MDA (mm)

1
2
3
4
5
6
Mean

0.86
0.77
0.88
0.78
0.82
0.86
0.83

2.71
2.17
2.69
2.54
2.78
3.35
2.71

0.98
0.87
0.79
1.04
0.91
0.87
0.91

Table 6: DSC, HD, and MDA between the segmented regions and predicted dose for the intra-treatment model.

Exposure #

DSC

HD (mm)

MDA (mm)

1
2
3
4
5
6
Mean

0.86
0.77
0.89
0.77
0.85
0.86
0.83

2.69
2.16
2.72
2.84
2.54
3.41
2.72

0.97
0.88
0.77
1.16
0.81
0.91
0.92

Table 7: DSC, HD, and MDA between the segmented regions and predicted dose for the post-treatment model.

5.4 Discussion
In this aim a novel methodology for fitting thermal dose models using MR data was
proposed and validated in phantoms. A logistic model was coupled to the traditional Arrhenius
equation to better account for the categorical EOIs commonly experienced in radiology. This multilevel model was reparametrized to facilitate the use of nonlinear optimization algorithms for finding
the Arrhenius parameters. The proposed technique theoretically confers several advantages over
traditional approaches to thermal dose modeling. First, the nonlinear optimization techniques
makes clinical and experimental ablation data available for model training. This better aligns the
derived model parameters with their intended application. Second, the addition of the logistic
model provides an additional mapping from thermal dose to the observed effect. This effectively
loosens the assumptions between the effect of interest and the underlying assumption of the
Arrhenius kinetics which may not be appropriate for all EOIs (including continuous EOIs). This model
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is not restricted to a logistic model and can be substituted for any model that’s tailored to particular
EOI provided that a corresponding likelihood function can be derived for optimization.
This new model fitting technique was validated in an egg-white phantom using both intratreatment (change in T1-W signal temperature dependence) and post-treatment EOIs (change in
T1). These models converged to solutions that are consistent with the range of values obtained by
van de Plancken et al.148,149 for two different EOIs (denaturation and turbidity). While the similarity
in the objective function surfaces suggest that the underlying processes are closely related, the
confidence intervals of these solutions do not overlap.
The areas predicted by both dose models compare favorably with the areas segmented on
post-treatment imaging when measured using DSC, HD, and MDA. In both cases DSC values
exceeded 0.8, which is considered good agreement in the context of radiology.115,152 The HD
measurements showed disagreement of 2-3mm (2-4 pixels) that can be primarily attributed to
artifacts caused by the presence of the laser. The mean distance to agreement was under 1mm for
both models which is small compared to the pixel size of 0.75mm. Each of the area comparison
metrics performed slightly better for the post-treatment model compared to the intra-treatment
model. This can be ascribed to the fact that the post-treatment model was trained to the same EOIs
and exposures that was used for evaluation whereas the intra-treatment model was trained to a
different (but related) EOI in a separate training group of exposures. However, the differences
(ΔDSC=0.01/ΔHD=0.08 mm/ΔMDA=0.06 mm) are so small that the model predicted areas can be
considered equivalent for practical purposes.
A third model that used changes in T2* as an intra-treatment isoeffect failed to converge to
a solution. Variations within this data prevented breakpoints from being identified consistently. The
temperature dependence of this data was inconsistent and a breakpoint could not be identified in
all pixels. Ultimately, 29% of the pixels were rejected using the AIC to prevent overfitting. This result
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suggests that changes in T2* are not a reliable indicators of Arrhenius processes in this phantom
setup. In contrast, Taylor et al.44 found opposite results regarding the utility of T1-W imaging and
T2* in ex vivo tissue. Further research is needed to evaluate the applicability of this parameter in
other samples.
While the experiments in this aim are sufficient for establishing the feasibility of the
proposed technique there are several areas where improvements can be made in future
experiments to enable additional characterization. One limitation of the phantom design was the
effect of melting agarose on MRTI measurements. This limited the number of exposures that could
be used for training the post-treatment model and effectively reduced the available lesion sizes.
Melting was also problematic when investigating other imaging effects such as magnetization
transfer (MT) and transverse relaxation (T2/T2*) rates since reliable changes in these parameters
were only observed at higher temperatures. This could be remedied by using higher melting point
agarose or switching to another MR visible gel with a higher melting point. Another alteration to the
experimental procedure would be to use isolated proteins for the measurements. Egg white is a
mixture of several proteins that denature with different kinetics. This would allow independent
verification in variety of different proteins while removing the uncertainty associated with having
mixed effects from multiple proteins.
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Application of Thermal Dose Models in vivo
6.1 Introduction
Post-treatment MRI, usually in the form of contrast-enhanced imaging, is often employed
immediately following thermal ablation therapies as the primary method of assessing the extent of
the thermal damage to tissue. These post-treatment images serve as a baseline for follow-up
imaging and are critical for monitoring for local progression.10,74 The availability of magnetic
resonance compatible delivery devices and the ability to monitor these therapies using real-time MR
temperature imaging has led to rapid adoption of these therapies in sensitive anatomic sites such as
the central nervous system. 153–157 Temperature feedback coupled with appropriate thermal dose
models facilitates periprocedural adjustments to maximize target coverage and reduce damage to
critical structures. 8,113 Together, treatment monitoring and post-treatment verification imaging help
provide a more complete assessment of the extent of therapy delivery.
Despite the outsized role radiologic appearance plays in treatment evaluation, existing
thermal dose models are not designed to be predictive of the radiologic changes that are ultimately
used for treatment assessment. Instead they rely on empirically derived parameters from laboratory
experiments that only approximate clinical endpoints8,97,102,113 or simplified models that may only be
applicable to a small subset of treatments158. Rather than deriving novel model parameters,
previous research in preclinical and clinical dose modelling has focused almost exclusively on
correlating dose estimates using existing models with radiologic observations for a narrow set of
procedures 114,118–120,159. This can be directly attributed to the mathematics that underlie the effects
of heat on tissue. However, as the frequency and types of MR-guided ablation procedures increases
there is a growing need and opportunity for developing methodologies that leverage existing clinical
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data to investigate novel dose models that are tailored to an expanding number of available
radiologic endpoints.160
In this work we develop and investigate a method for fitting novel thermal dose models
using intra-operative MR imaging during laser ablation of brain metastases in human subjects. The
high temporal and spatial resolution of MRTI is combined with nonlinear optimization techniques
and logistic modeling to overcome the challenges that have traditionally restricted these types of
studies to the laboratory. To demonstrate the feasibility of developing models in this manner, two
models are investigated that predict the size of the non-enhancing central region and enhancing ring
that are characteristic of thermal lesion on post-treatment contrast-enhanced T1-weighted imaging.
A third model is examined that seeks to interpret these regions in terms of probability of tissue
viability. These parameters are compared to several other models that have been investigated for
use during thermal ablation therapies. The predicted areas are then compared to the areas
segmented on post-treatment imaging and the areas predicted by two clinically used dose models.

6.2 Methods
6.2.1 Lesion Selection and Image Processing
Intra operative MR temperature imaging estimates and post-treatment contrast-enhanced
imaging were retrospectively analyzed for 5 intracranial metastatic lesions (2 melanoma/3 breast; 2
male/3 female; age range: 57-69) treated using a 15W 980nm laser with a single, water cooled laser
applicator (Visualase, Medtronic, Minneapolis, MN, USA) on a 1.5T MRI (MAGNETOM Espree,
Siemens Healthcare, Erlangen, Germany). MRTI was acquired in two orthogonal planes using a
dynamic, radiofrequency spoiled gradient echo pulse sequence (TR=24 ms, TE=15 ms, α=30°,
acquisition matrix=256x128 , field of view= 26 x 26 cm, slice thickness=3 mm, RBW = 80 Hz/pixel,
time between phases=6s) and temperature estimates were calculated by applying the complex
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phase difference technique to Wiener filtered complex data (3x3 kernel) in MATLAB (R2015a,
MathWorks, Natick, MA, USA) using a temperature sensitivity coefficient of -0.01ppm/°C27. To
account for drift in the main magnetic field, the apparent temperature increase in a 15x15 pixel ROI
in a region far from heating was subtracted from the temperature maps. In cases where transient
shifts in the magnetic field were observed, temperature maps were linearly interpolated in the
temporal direction and a new baseline image was selected. Lesions treated with multiple fibers or
containing major MRTI artefacts were excluded to ensure the accuracy of the MRTI data.
Each lesion was imaged before and after treatment using a 3D T1-weighted spoiled gradient
echo sequence with and without contrast (TR=5.25 ms, TE=2.5 ms, α=15°, acquisition
matrix=256x256, field of view= 28 x 28 cm, slice thickness=1.25 mm, RBW= 400 Hz/pixel). The 3D
series that preceded the MRTI acquisition was identified as the target series for 3D image
registration and distortion correction was kept consistent across all series.
Each 3D series was converted from DICOM file format to the Neuroimaging Informatics
Technology Initiative (NIfTi) format161 and skull stripped162to facilitate image registration. An affine
registration161 was used to register each series to the target series and accuracy was assessed
qualitatively by verifying the position of the laser fibers.
The region of contrast enhancement was segmented manually (Amira 5.4.2, FEI, Hillsboro,
OR, USA) using pre-treatment subtraction images to delineate the gross tumor volume. On posttreatment subtraction images, the non-enhancing central region and enhancing ring were
segmented to define the thermal ablation lesion. The registered T1-weighted images and
segmentations were then resampled161 into the 2D geometry of the MRTI acquisition so that
temperature histories could be linked to the segmentation data on a per pixel basis. After
resampling, the outer edge of the enhancing ring was dilated using a 5x5 kernel (≈5mm) to define an
outer non-enhancing region where there was temperature increase but no radiologic change.
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6.2.2 Inner/Outer Boundary Models
For post-treatment contrast-enhanced imaging the radiologic features of interest are the
boundaries between the central nonenhancing region and the enhancing ring (inner boundary) and
the enhancing ring and the outer nonenhancing region (outer boundary). A model for the inner ring
boundary was created by assigning all pixels in the central nonenhancing region 𝑦 = 1 and all pixels
in the enhancing ring and outer nonenhancing region 𝑦 = 0. Similarly, a model of the outer ring
boundary was created by assigning all pixels in the central nonenhancing region and enhancing ring
𝑦 = 1 and those in the outer nonenhancing region 𝑦 = 0. Pixels that enhanced on both pre and
post-treatment subtraction images were excluded from the outer boundary model since it is
ambiguous whether their enhancement is due to treatment effect or residual tumor. Data in these
regions would be inappropriate for training our model as the logistic regression demands we know
the fraction of damaged tissue and no assumptions can be made in these areas.

Figure 6-1: Tumor/thermal lesion segmentations and model regions for boundary models. The segmented
tumor (blue) and the thermal lesion defined by the central nonenhancing region (red dotted) and enhancing
ring (red solid) with skull-stripped post-treatment post-contrast image in the background (A). The regions
classified as y=1 (yellow) and y=0 (cyan) for the inner boundary (B), outer boundary (C), models with skullstripped post-treatment post-contrast image in the background. The area adjacent to the skull has been
excluded due to uncertainty in the segmentation and the area of ambiguous enhancement was excluded in the
outer boundary model (C).

Temperature histories for each patient were grouped together to generate a patient
averaged model of the inner/outer boundaries with optimal dose thresholds chosen to minimize the
sum of false positives and false negatives. The inner and outer boundary models were fit using 4,676
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and 4,337 pixels, respectively. The Arrhenius parameters of both of these models were compared to
7 values from the literature.
In the special case of the CEM model, equations 3-10 and 3-13 were used to calculate the
Arrhenius parameters for the CEM model parameters at high temperatures (𝑇0 = 43°C; R 𝐶𝐸𝑀 =
0.5) to reflect the effective parameters used in the literature. A summary of each model and its
corresponding EOIs are shown in Table 8. The inner and outer boundary Arrhenius parameters were
also used to calculate the equivalent 𝑅𝐶𝐸𝑀 and 𝑇𝑐 ′ using equations 3-13 and 3-16 respectively.
Optimal dose thresholds were also calculated using the traditional CEM model (𝐶𝐸𝑀𝑡ℎ𝑟𝑒𝑠ℎ ) and the
maximum temperature (𝑇𝑐 ) for direct comparison to previous work in the literature.
The radiological feature models were compared to the segmentations using the DSC, HD,
and MDA metrics described in 5.2.4. After comparing the radiologic features models to the
segmented regions they were compared to the two dose models used in FDA cleared systems to get
an understanding of the impact of the new models in a clinical scenario. Dose thresholds of Ω=1113
and CEM=2, 10, 60, and 240 minutes at 43°C8 were used for the Henriques model and CEM model,
respectively.
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Log Frequency Factor, Activation Energy, 𝐸𝐴
log(𝐴)

Study
Henriques†97 227

CEM*†

102

210

[kJ/mol]

Effect of Interest (EOI)
Second degree burns;

628

porcine skin (in vivo)
Various (in vivo/ex vivo) 163

578

Protein denaturation; whole
64.2

Qin 108

cells;

189

DSC with 𝑇𝑚𝑎𝑥 = 60℃
Protein denaturation; whole
145

Qin 108

cells;

401

DSC with 𝑇𝑚𝑎𝑥 = 50℃
Optical scattering
Jacques‡ 103 87.2

258

coefficient;
porcine liver (ex vivo)

Borelli‡ 104

185

506

Brown‡ 105

245

667

Cell survival;
baby hamster kidney cells
Microvasculature disruption;
murine muscle (in vivo)

†Used in FDA cleared ablation system
*Calculated assuming R=0.5 and equations 3-10 and 3-13
‡Associated with inner/outer ring boundaries on T2-weighted imaging by Sherar et al. 114
Table 8: Selected Arrhenius parameters from literature.

6.2.3Tissue Viability Model
The primary limitation of the radiologic feature models is that they provide no direct
information on the viability of the tissue. Real-time prediction of the inner and outer ring
boundaries still requires interpretation of a physician when making treatment decisions. Several
studies have examined the viability of tissue in each of the segmented regions and there is
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considerable ambiguity in the fate of tissue in the enhancing ring.81,81,83,84,86,87,119 However, if pixels in
the central nonenhancing region are assumed irreversibly damaged (𝑦 = 1) and pixels in the outer
nonenhancing region are assumed to viable (𝑦 = 0) the resulting model can be interpreted as a
model of tissue viability. (Figure 6-2) This a subtle but significant difference from the inner/outer
boundary models where the objective was to find a threshold that best classifies pixels as being on
either side of a boundary. Here thresholds are chosen a priori that represent the amount of isoeffect
of practical clinical interest.
Similar to the inner/outer ring boundary models, a patient averaged model was calculated
using data from all patients. A series of tissue viability thresholds (10%, 50%, and 90%) were
examined that represent different degrees of confidence in tissue viability. These can be interpreted
as the thresholds for onset of irreversible damage, equal likelihood of viability and nonviability, and
almost certain tissue nonviability, respectively. Since no radiologic gold standard measure of tissue
viability exists, the areas predicted by the cell viability model were compared to the two clinical
utilized dose models using the DSC, MDA, and HD.

Figure 6-2: Tumor/thermal lesion segmentations and model regions for tissue viability model. The segmented
tumor (blue) and the thermal lesion defined by the central nonenhancing region (red dotted) and enhancing
ring (red solid) with skull-stripped post-treatment post-contrast image in the background (A). The regions
classified as nonviable (y=1; yellow) and viable (y=0; cyan) for the tissue viability (B) model with skull-stripped
post-treatment post-contrast image in the background. Pixels in the enhancing ring are interpreted as
nonviable while
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6.3 Results
6.3.1 Arrhenius Parameter Optimization
To evaluate the convergence of the optimization algorithm the negative log likelihood was
calculated over the range of 𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 )/𝐸𝐴 values commonly found in the literature. For each model
there is a single local minimum where the surface is smooth and convex. These solutions and 95%
confidence ellipses are plotted in the 𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 )/𝐸𝐴 reference space along with selected literature
values for comparison for the inner/outer boundary models (Figure 6-3a-b) and tissue viability
model (Figure 6-4a). The axis limits in this figure were deliberately chosen to represent the upper
limits of the values observed in the literature. The advantages of the reparameterization in equation
3-10 are apparent when the same data is plotted in the traditional 𝑙𝑜𝑔(𝐴)/𝐸𝐴 space (Figure 6-3c;
Figure 6-4c). The high correlation between parameters causes the confidence ellipses to appear as
lines and makes visual comparison using the confidence regions and literature values nearly
impossible. The confidence ellipses do not overlap, suggesting that all three models are distinct and
that the differing values are not a statistical consequence of the compensation law. The parameters
that define these ellipses are given in Table 9.
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Figure 6-3: Optimal Arrhenius parameters for inner/outer boundary models. The optimal Arrhenius parameters
(green circle) and 95% confidence regions (green) are shown with the negative log likelihood in the background
in the 𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 ) /𝐸𝐴 parameter space for the inner boundary (A) and outer boundary (B) models. The same
data is shown in the 𝑙𝑜𝑔(𝐴) /𝐸𝐴 parameter space (C). The Arrhenius parameters (magenta) from Henriques
(♦), CEM (●), Qin (𝑇𝑚𝑎𝑥 = 60℃;▲), Qin (𝑇𝑚𝑎𝑥 = 50℃;▼), Jacques (✱), Borelli (■), and Brown (⋆). The
empirical linear relationship between 𝐸𝐴 and 𝑙𝑜𝑔(𝐴) (black line) is also plotted for reference.
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Figure 6-4: Optimal Arrhenius parameters for tissue viability boundary model The optimal Arrhenius
parameters (green circle) and 95% confidence regions (green) are shown with the negative log likelihood in the
background in the 𝑙𝑜𝑔(𝐴𝑅𝑒𝑓 ) /𝐸𝐴 parameter space (A). The same data is shown in the 𝑙𝑜𝑔(𝐴) /𝐸𝐴 parameter
space (C). The Arrhenius parameters (magenta) from Henriques ( ♦), CEM (●), Qin (𝑇𝑚𝑎𝑥 = 60℃;▲), Qin
(𝑇𝑚𝑎𝑥 = 50℃;▼), Jacques (✱), Borelli (■), and Brown (⋆). The empirical linear relationship between 𝐸𝐴 and
𝑙𝑜𝑔(𝐴) (black line) is also plotted for reference.

6.3.2 Optimal Model Parameters
The Arrhenius parameter values of the inner boundary model are lower than the outer
boundary model and span activation energies from 143kJ/mol to 182 kJ/mol. They do not overlap
with any of the models from the literature but are closest to the coefficients reported by Jacques
and Qin (𝑇𝑀𝑎𝑥 = 60℃). These coefficients correspond to equivalent 𝑅𝐶𝐸𝑀 values and 𝑇𝑐 ′ values of
0.82 and 94.5⁰C, respectively. The outer boundary model has higher coefficient values that span
activation energies of 384 kJ/mol to 506kJ/mol. Like the inner boundary model, these coefficients do
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not overlap with any of those found in the literature but they are closest to coefficients of the CEM,
Qin (𝑇𝑀𝑎𝑥 = 50℃), and Borrelli models. The activation energy of the Borelli and Qin (𝑇𝑀𝑎𝑥 = 50℃)
model is consistent with the values of the outer boundary model but a difference in the frequency
factor prevents it from overlapping with the confidence ellipse. These coefficients correspond to
equivalent 𝑅𝐶𝐸𝑀 values and 𝑇𝑐 ′ values of 0.59 and 57.3⁰C, respectively. In both models the
confidence ellipses imply a linear relationship between 𝑙𝑜𝑔(𝐴) and 𝐸𝐴 with slopes and intercepts
that are larger than used in equation 3-10.
The 95% confidence interval of the tissue viability model is centered on 445 kJ/mol and
spans energies from 293 kJ/mol to 553 kJ/mol. The activation energy of the outer boundary model
are within the range activation energies of the tissue viability model but they do not overlap due to
a difference in the values of log(𝐴). The confidence interval is also approximately twice the size of
the outer boundary model which is direct consequence of excluding pixels in the enhancing ring.
This solution does not overlap with any of the literature values but the activation energies are
consistent with the Borelli and Qin (𝑇𝑀𝑎𝑥 = 50℃) models. The Jacques and CEM models are also
just outside the lower and upper edges of the confidence interval, respectively. Similar to the inner
and outer boundary models the confidence intervals imply a slope that is larger than equation 3-10.
These Arrhenius parameters imply 𝑅𝐶𝐸𝑀 =0.60 and a𝑇𝐶 ′ of 62.1°C.
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Inner Boundary

Outer Boundary

Model
Activation Energy, 𝐸𝐴 [kJ/mol] 162

Viability

Model

Model

445

423

53.0

161

152

Minor axis length

0.187

0.251

0.350

Major axis length

20.8

65.4

139.7

Slope [kJ-1]

0.366

0.376

0.3721

Intercept

-6.25

-6.99

-5.90

𝑅𝐶𝐸𝑀

0.82

0.59

0.60

𝑇𝐶 ′ [°C]

94.5

57.3

62.1

Log Frequency Factor, log(𝐴)
[s-1]

Table 9: Optimal Model Parameters and 95% Confidence Ellipses

6.3.3 Optimal Boundary Model Thresholds and Viability Thresholds
Figure 6-5 shows the probability of being within the model region as a function of 𝐹𝐶 along
with the thresholds that optimize the accuracy of the boundary models model. The optimal
threshold for the inner boundary model is a thermal dose of Ω=0.99/𝐹𝐶 = 0.63. This threshold is
coincidentally effectively equal to the historically used threshold of Ω=1. The optimal threshold for
the outer boundary model is a thermal dose of Ω=0.22/𝐹𝐶 = 0.20. (Table 10) Both models
performed extremely well, with areas under the curve and accuracy in excess of 0.95 and 85%,
respectively. The values 𝐶𝐸𝑀𝑆𝐷−𝑡ℎ𝑟𝑒𝑠ℎ were 1.8x105 min. and 32 min. for the inner and outer
boundaries, respectively. 𝑇𝑐 was found to be 61.5°C and 47.6°C for the inner and outer boundaries,
respectively.
The relationship between 𝐹𝐶 and tissue viability is shown in Figure 6-6. The dose thresholds
that correspond to 10, 50, and 90% probability of viability were Ω=0.31/𝐹𝐶 = 0.37, Ω=0.49/𝐹𝐶 =
83

0.68, and Ω=0.66/𝐹𝐶 = 1.07, respectively (Table 11). Excellent classification (AUC=1.00;
accuracy=0.99) is maintained at all 3 thresholds due to the exclusion of pixels in the enhancing ring.

Figure 6-5: Inner and outer boundary logistic models The probability of being contained within the inner (A)
and outer boundary (B) as a function of fractional conversion using the optimal Arrhenius parameters in table
1. The threshold that maximizes the accuracy is shown in cyan. The false positive (blue) and true negative rates
(red) are shown for reference.

Inner Boundary Model

Outer Boundary Model

𝑘

7.80

7.11

𝐹𝐶50

0.608

0.255

AR Model Thresholds (𝑦̂/𝐹𝐶/𝛺)

0.542/0.630/0.994

0.399/0.197/0.219

Table 10: Optimal Logit Parameters and Thresholds for the Inner and Outer Boundary Models
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Figure 6-6: Tissue viability logistic model.The probability of tissue viability as a function of fractional conversion
using the optimal Arrhenius parameters in table Table 9. The threshold that maximizes the accuracy is shown
in cyan. The false positive (blue) and true negative rates (red) are shown for reference.

𝑦̂ = 10%

𝑦̂ = 50%

𝑘

12.37

𝐹𝐶50

0.51

AR Model Thresholds (𝐹𝐶/𝛺)

0.31/0.37

0.49/0.68

𝑦̂ = 90%

0.66/1.07

Table 11: Dose thresholds for tissue viability model

6.3.4 Model Predicted Region Comparison
Figure 6-7 shows a representative comparison between the areas predicted by the
inner/outer boundary models and the segmentations (a), the Henriques model (b), and CEM model
(c) for the three clinically used dose thresholds. The mean DSC/DTA/HD between the boundary
models and segmentations was 0.87/0.93 mm/2.92 mm and 0.89/ 1.1 mm/3.5 mm for the inner and
outer boundary models, respectively. In both cases the mean DTA is on the order of the pixel size (1
mm). There is consistent disagreement at the edge of the skull in Figure 6-7 that is likely caused by
partial voluming which underscores the need to remove selected areas from model fitting. On
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average the Henriques dose model fell between the predicted inner and outer ring boundaries with
a MDA of 1.5 mm from each boundary. The CEM model using a threshold of 60 minutes practically
indistinguishable from the outer ring model with a DSC/DTA/HD of 0.98/0.24 mm/0.99 mm. The 240
and 10 minute thresholds were just inside and outside the outer boundary model and agreed within
a pixel size with a DSC/DTA/HD of 0.91/2.17 mm/0.84 mm and 0.92/0.88 mm /2.93 mm,
respectively. The Jacques, Borelli, and Brown models show excellent agreement with the outer and
inner boundary models as previously investigated by Sherar et al. with DSC/DTA/HD = >0.96/<0.38
mm/<1.22 mm.114
The areas predicted by the tissue viability model are practically indistinguishable (MDA<0.75
mm (pixel size)) from one another so only the 50% viability threshold is shown in Figure 6-8 for
clarity. These thresholds are closest to the areas predicted by the Henriques and CEM model using a
threshold of 240 minutes. A complete comparison between all of the models for each metric is given
in Appendix 2 for reference.

Figure 6-7 Isodose lines predicted by the inner and outer boundary models compared to the inner and outer
boundary segmentations (A), Henriques model (B), and CEM model (C).
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Figure 6-8: Isodose lines predicted by the tissue viability model compared to the inner and outer boundary
segmentations (A), Henriques model (B), and CEM model (C).

6.4 Discussion
In this work a technique for deriving thermal dose models from intra-operative MR data
acquired during thermal ablation is developed and its feasibility is demonstrated using clinical laser
ablation data. To address challenges typically associated with these measurements, a coupled ARlogistic model of thermal dose and nonlinear optimization techniques were employed. This
approach makes the ever expanding amount of clinical ablation data available for training thermal
dose models that are predictive of clinically utilized radiologic endpoints and represents a significant
shift from dose models based on non-clinical endpoints in non-human samples. However, special
care must be taken to ensure that only data free of artifacts and errors should be utilized for model
development.
In this work demonstrating feasibility, post-treatment contrast-enhanced images were used
as a radiologic endpoint. As implemented, this technique can be generalized to any available
radiologic endpoint, such as diffusion, perfusion, or magnetization transfer based techniques,
provided that they can be reliably and accurately registered to the MRTI dataset. However, if the
EOI cannot be reliably modeled as a first order rate process as a function of temperature, changes in
the underlying approach to modeling will be required. The proposed approach is also agnostic to the
modality used to deliver the thermal therapy and can be applied to any procedure where MRTI is
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acquired with sufficient spatial and temporal resolution. This flexibility enables in vivo investigation
models that are disease, tissue, and procedure specific. It is important to note that since this
approach focuses on radiologic endpoints as pragmatic way of unifying treatment monitoring and
assessment, the prediction of tissue viability is only as reliable as the surrogate imaging marker
used. Additional research is needed to validate the procedure investigated here by correlating
predicted damage to remaining viable tissue.
The inner and outer boundary models compare favorably to similar investigations found in
the existing literature. The ranges of 𝐶𝐸𝑀𝑆𝐷−𝑡ℎ𝑟𝑒𝑠ℎ and 𝑇𝑐 are consistent with similar investigations
in the literature8,27,114,115,119,120. Sherar et al. found that the model developed by Jacques correlated
well with the inner boundary while the Brown and Borelli models correlated well with the outer
boundary measured using T2-weighted imaging. For the laser heating in brain neoplasms analyzed
here, our inner and outer boundary model solutions are consistent with these findings both in terms
of the Arrhenius parameters and the model predicted regions. Additionally, the inner and outer
boundary Arrhenius values derived from the patient data are consistent with the average effective
activation energies for overall protein denaturation in 4 different cell lines measured by Qin et al if
the critical temperature, 𝑇𝑐 , is used as a surrogate for the maximum temperature (𝑇𝑐 =61.5°C and
47.6°C for the inner and outer boundary model, respectively). This suggests that post-treatment
contrast-enhanced imaging may be an appropriate surrogate for the denaturation of major cellular
proteins.
The models investigated here can provide additional insight into the utility of each thermal
dose model. The AR model was optimized because it relies on only few simplifying assumptions and
should be accurate over a large range of different time-temperature histories. The AR model
parameters can also be conveniently converted into CEM and CT model coefficients using equations
3-10 and 3-16. The equivalent R 𝐶𝐸𝑀 values (0.82, 0.59, 0.60 for inner boundary, outer boundary,
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and viability models, respectively) were substantially higher than the commonly used R 𝐶𝐸𝑀−𝑆𝐷 =
0.5. Dewhirst reported a R 𝐶𝐸𝑀 of 0.72 for 𝑇 > 47℃for the Henriques skin burn data but also
cautioned that there is high uncertainty because the assumption of isothermal exposure was likely
violated at high temperatures in the original experiment. 164 However, the technique described here
does not require an isothermal exposure, suggesting that further work should be performed to see if
increased R 𝐶𝐸𝑀 values are appropriate when applying the CEM model to ablation procedures.
Comparison of the model predicted regions with dose models that are currently being used
clinically is of practical interest. On average, the Henriques model was halfway between the inner
and outer boundaries of the thermal lesion, suggesting that it may represent a conservative
estimate of the size of the thermal lesion. The 60 min. CEM threshold appears to accurately reflect
the size of the outer boundary with the 240 min. and 10 min. thresholds predicting slightly smaller
and larger areas, respectively. For the viability model, the transition region between viable and
nonviable tissue occurred very rapidly compared to the spatial resolution of MRTI. The close
agreement between the areas predicted by the viability model and the Henriques and CEM240
predicted areas suggests that these models are most consistent with the underlying assumptions of
the viability model. Further study is needed to investigate if these results are consistent within a
larger patient population and how they relate to clinical outcomes after extended follow up.
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Discussion
In this work we proposed and demonstrated the feasibility of a methodology for deriving
novel thermal dose model parameters exclusively from MR data acquired during thermal ablation
procedures. This approach was investigated for intra- and post-treatment effects of interest in
protein coagulation phantom (SA2) using a customized multi-parametric pulse sequence (SA1)
before being applied retrospectively to clinical laser ablation cases where the appearance of the
thermal lesion on post-treatment contrast-enhanced imaging served as an effect of interest (SA3).
The optimal Arrhenius parameters and predicted regions were consistent with expected values in
both the phantom and clinical data. Using this approach, thermal dose model parameters can be
tailored to clinically relevant EOIs. This represents a paradigm shift away from existing model
parameters that are derived from laboratory experiments and can only be considered surrogates for
clinical effects. The ability to derive thermal dose model parameters specific to clinical EOIs is
increasingly important as the number of clinical ablation procedures continues to grow and
additional EOIs become incorporated into clinical workflow.
While this methodology can be used to understand kinetics that govern the radiologic
appearance of the thermal lesion, it does not provide any new information on the biological state of
tissue. Thus, the clinical interpretation of these models can only be as useful as the underlying
knowledge of how the appearance of the thermal lesion translates to a particular biological effect. A
tissue viability model was investigated in specific aim 3 by integrating knowledge of the biologic
state of tissue directly into the definition of the EOI. This approach allows the dose models to be
interpreted in terms of a biological effect rather than simply a radiologic effect and is especially
important when evidence for using multiple complementary EOIs for evaluating thermal lesions is
considered. This underscores the need for continued research into the correlation of imaging with
histopathologic endpoints.
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Another key advantage of this methodology is the amount of data it makes available for
training dose models. Each clinical procedure has the potential to be used for continued refinement
of dose model parameters. As the amount of data increases the predictive value of the model
parameters can be rigorously assessed using training and validation cohorts. This also allows
stratification based on the tissue and procedure type that could lead to highly specific models of
thermal damage. As these models become more refined and are correlated with clinical outcomes
(e.g. local progression) there is an opportunity for thermal dose to assume a major role in these
procedures that’s more akin to that used in radiation oncology. While this line of research remains
to be investigated, the methodology in this work removes significant technical barriers.
While the immediate clinical implications of this work are predominantly focused on posttreatment EOIs, the methodology described here was also extended to intra-treatment EOIs. There
is relatively little research into these types of EOIs despite them being observed for several intrinsic
MR parameters and being associated with irreversible changes in tissue. Dynamically measuring
quantitative parameters is theoretically the ideal monitoring strategy for investigating these EOIs
but the results of this work highlights the fact that alterations to acquisition strategy to this end may
not always be necessary or optimal. Changes in T1-W signal were sufficient for training an Arrhenius
model in the protein coagulation phantom while a model using quantitative measurements of T2*
did not converge. Further research is needed to investigate these types EOIs on case by case basis to
help inform the optimal acquisition strategies and detection algorithms. If these EOIs can be
characterized with consistency they may be able to complement existing post-treatment effects.
While the hypothesis that Arrhenius models could be determined using in vivo MR data was
confirmed, many avenues for future research remain. T1 quantification was complicated by the
simultaneous effects slice profile and B1 inhomogeneities. Several methods for mitigating one or
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both of these effects were mentioned in Chapter 4. Future experiments should focus on extending
similar modifications to 3D sequence and/or controlling the RF pulse shape in the 2D sequence.
These represent the easiest ways to achieve quantitative T1 values and would allow a rigorous
evaluation of the utility of obtaining quantitative T1 measurements for measuring intra-treatment
EOIs.
The protein phantom in Chapter 5 provided a controlled setup for measuring Arrhenius
parameters in a sample that can be easily compared to the literature. A variety of isolated proteins
(e.g. bovine serum albumin) are available and should be studied to further establish the technique.
Melting of agarose corrupted temperature data in these experiments which effectively reduced the
maximum lesions size and prevented other EOIs such as magnetization transfer, T2-W, and diffusion
from being investigated. Future experiments should implement real-time monitoring should be
integrated into the scanner so that high temperatures can be avoided entirely. Additionally, other
gels and/or heating methods should be considered to further reduce the probability of melting in
the gels. With these experimental improvements future experiments should be designed to have
both calibration and validation cohorts for both types of EOIs.
The primary focus of future work for in vivo data should focus on streamlining imaging
protocols to acquire additional EOIs and clinical outcomes. This includes paying close attention to
distortion correction, additional acquisitions to facilitate image registration, and avoiding MRTI
artifacts. Each of these were frequently encountered during data selection in Chapter 6. While it
may not be realistic to expect significant in clinical workflow, any attempt to reduce these errors
would expand the number of available datasets. As the number of patients is increased the
Arrhenius models should be fit independent calibration and validation sets and stratified by the
underlying pathology. This work also only used laser ablations using one vendor’s laser ablation
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system. This image processing should be adapted to these additional datasets to both increase the
number of patients and to assess any differences between vendors.
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Appendix 1: Pulse Sequence and Exposure Parameters from Chapter 5
Group A
Field of View (cm)

Group B

Group C

19.6

19.6

19.6

19.2

19.2

19.2

19.2

19.2

19.2

19.2

19.2

19.2

19.2

19.2

19.2

19.2

19.2

Repetition Time (ms)

35

35

35

35

35

35

35

35

35

35

35

70

70

70

100

100

100

Echo Train Length

8

8

8

8

8

8

8

8

8

8

8

8

8

8

8

8

8

Minimum Echo Time (ms)

2.1

2.1

2.1

1.8

1.8

1.8

1.8

1.8

1.8

1.8

1.8

1.8

1.8

1.8

1.8

1.8

1.8

Echo Spacing (ms)

2.5

2.5

2.5

2.1

2.1

2.1

2.1

2.1

2.1

2.1

2.1

2.1

2.1

2.1

2.1

2.1

2.1

Receive Bandwidth (Hz/pixel)

195

195

195

326

326

326

326

326

326

326

326

326

326

326

326

326

326

Flip Angle (°)

30

30

30

30

30

30

30

30

30

30

30

25

25

25

25

25

25

Number of Slices

1

1

1

1

1

1

1

1

1

1

1

3

3

3

3

3

3

mfa_mode

1

1

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

mfa_low_flip

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

2

4.8

4.8

4.8

4.8

4.8

4.8

4.8

4.8

4.8

4.8

4.8

7.9

7.9

7.9

12.4

12.4

12.4

Time between phases (s)

Table 12: Pulse sequence parameters for phantom experiments in Chapter 5
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8 min@10W
Group A

8 min@12W
8 min@14W
9 min@10W
5 min@15W; 1 min@0W; 2 min@15W
9.5 min@11.5W

Group B

1.5 min@15W; 7 min@11.5W
2 min@15W;7.5min@12.5W
2 min@15W;7.5 min@12.5W
2 min@15W; 5 min@12.5W; 1 min@13.5W; 1.5 min@12.5W
16 min@12.5W
10 min@10W
12 min@7.5W

Group C

11 min@8.75W
14 min@7.5W
12 min@8.25W
17 min@7.5

Table 13: Laser exposure parameters for experiments in Chapter 5. All changes to laser powers are consecutive with minimal interruption (<1 second).
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Appendix 2: DSC, HD, and MDA for Segmentations and Models in Chapter 6
Inner Seg. Outer Seg.

Inner
Outer
Henriques
Boundary Boundary

CEM
(2 min.)

CEM
(10 min.)

CEM
(60 min)

CEM
(240 min.)

Jacques

Borelli

Brown

Viability
10%

Viability
50%

Inner Seg.

1.00

Outer Seg.

0.66

1.00

0.87

0.64

1.00

0.69

0.89

0.67

1.00

0.83

0.79

0.83

0.83

1.00

0.54

0.83

0.52

0.83

0.67

1.00

0.62

0.88

0.60

0.92

0.76

0.90

1.00

0.71

0.89

0.69

0.98

0.85

0.80

0.90

1.00

0.77

0.86

0.75

0.91

0.92

0.74

0.83

0.93

1.00

Jacques

0.87

0.61

0.96

0.63

0.79

0.49

0.57

0.65

0.71

1.00

Borelli

0.68

0.90

0.66

0.99

0.82

0.83

0.93

0.97

0.90

0.63

1.00

Brown

0.72

0.89

0.70

0.96

0.87

0.79

0.88

0.99

0.95

0.67

0.96

1.00

Viability 10%

0.77

0.86

0.75

0.91

0.92

0.74

0.83

0.93

0.99

0.72

0.90

0.94

1.00

Viability 50%

0.76

0.87

0.74

0.92

0.90

0.75

0.85

0.95

0.99

0.70

0.92

0.96

0.98

1.00

Viability 90%

0.81

0.82

0.80

0.86

0.97

0.70

0.79

0.88

0.95

0.76

0.85

0.90

0.95

0.94

Inner
Boundary
Outer
Boundary
Henriques
CEM
(2 min.)
CEM
(10 min.)
CEM
(60 min)
CEM
(240 min.)

Table 14: DSC Values for the segmentations and models in Chapter 6
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Viability
90%

1.00

Inner Seg. Outer Seg.

Inner
Boundary

Outer
Henriques
Boundary

CEM
(2 min.)

CEM
(10 min.)

CEM
(60 min)

CEM
(240 min.)

Jacques

Borelli

Brown

Viability
10%

Viability
50%

Inner Seg.
Outer Seg.
Inner
Boundary
Outer
Boundary

5.55
2.92

6.25

5.65

3.47

6.07

3.58

4.05

3.37

3.23

8.13

4.66

8.68

4.65

6.66

6.86

4.00

7.43

2.93

5.23

3.04

5.41

3.35

5.75

0.99

2.93

5.02

3.47

4.47

3.35

4.58

2.17

1.64

5.76

4.35

1.81

Jacques

2.61

6.15

1.11

5.91

3.24

8.54

7.21

5.60

4.48

Borelli

5.76

3.47

6.18

0.47

3.36

4.48

2.76

1.15

2.32

6.02

Brown

5.23

3.31

5.54

1.22

2.71

5.19

3.65

0.60

1.58

5.42

1.40

Viability 10%

4.33

3.47

4.43

2.34

1.46

5.88

4.44

2.03

0.62

4.34

2.49

1.84

Viability 50%

4.64

3.39

4.82

1.97

1.91

5.62

4.21

1.67

0.56

4.72

2.14

1.42

0.81

Viability 90%

3.88

3.83

3.76

2.97

0.76

6.38

5.03

2.69

1.31

3.64

3.10

2.46

1.06

Henriques
CEM
(2 min.)
CEM
(10 min.)
CEM
(60 min)
CEM
(240 min.)

Table 15: HD Values for the segmentations and models in Chapter 6
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1.57

Viability
90%

Inner Seg. Outer Seg.

Inner
Boundary

Outer
Henriques
Boundary

CEM
(2 min.)

CEM
(10 min.)

CEM
(60 min)

CEM
(240 min.)

Jacques

Borelli

Brown

Viability
10%

Viability
50%

Inner Seg.
Outer Seg.
Inner
Boundary
Outer
Boundary

2.93
0.94

3.19

2.77

1.06

2.98

1.43

1.80

1.50

1.51

4.57

1.88

4.84

1.87

3.34

3.56

1.23

3.81

0.88

2.32

1.07

2.57

1.04

2.79

0.24

1.32

2.06

1.06

2.02

1.30

2.18

0.84

0.75

2.65

1.64

0.66

Jacques

0.95

3.38

0.29

3.19

1.70

5.04

4.01

3.00

2.39

Borelli

2.85

1.05

3.07

0.12

1.59

1.79

0.79

0.33

0.93

3.27

Brown

2.43

1.08

2.64

0.38

1.19

2.20

1.20

0.18

0.51

2.85

0.48

Viability 10%

1.95

1.36

2.10

0.93

0.66

2.75

1.73

0.75

0.13

2.31

1.02

0.61

Viability 50%

2.11

1.25

2.28

0.76

0.83

2.58

1.56

0.58

0.13

2.48

0.85

0.43

0.22

Viability 90%

1.63

1.61

1.73

1.29

0.27

3.13

2.11

1.11

0.53

1.94

1.38

0.97

0.43

Henriques
CEM
(2 min.)
CEM
(10 min.)
CEM
(60 min)
CEM
(240 min.)

Table 16: MDA Values for the segmentations and models in Chapter 6
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0.61

Viability
90%
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